<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003546.pub2" GROUP_ID="SCHIZ" ID="947900122000154153" MERGED_FROM="" MODIFIED="2012-10-17 10:55:20 +0100" MODIFIED_BY="Claire Irving" REVIEW_NO="1" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2012-10-17 10:55:20 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Management of sexual dysfunction due to antipsychotic drug therapy</TITLE>
<CONTACT MODIFIED="2012-10-17 10:55:20 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="E1682DE482E26AA201DAB7D8016E5C44" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Berner</LAST_NAME><EMAIL_1>dr.m.berner@rhein-jura-klinik.de</EMAIL_1><EMAIL_2>berner@nz.ukl.uni-freiburg.de</EMAIL_2><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>Rhein-Jura Klinik</ORGANISATION><ADDRESS_1>Schneckenhalde 13</ADDRESS_1><CITY>Bad Säckingen</CITY><ZIP>D-79713</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-17 10:55:20 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="18800421808842052473120711095610" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Hannah</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Schmidt</LAST_NAME><EMAIL_1>hannah.schmidt@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University Medical Center Freiburg</ORGANISATION><ADDRESS_1>Hauptstrasse 5</ADDRESS_1><CITY>Freiburg im Breisgau</CITY><ZIP>D-79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="1184FB3D82E26AA201DC7B3E11929F35" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Mathias</FIRST_NAME><LAST_NAME>Hagen</LAST_NAME><POSITION>Medical Student</POSITION><EMAIL_1>m-hagen@gmx.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University Medical Center Freiburg</ORGANISATION><ADDRESS_1>Hauptstrasse 5</ADDRESS_1><CITY>Freiburg im Bresigau</CITY><ZIP>D-79104</ZIP><REGION>Baden-Württemberg</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761 270 6501</PHONE_1><FAX_1>+49 761 270 6619</FAX_1></ADDRESS></PERSON><PERSON ID="C55EFE5082E26AA20130726F0964539D" ROLE="AUTHOR"><FIRST_NAME>Levente</FIRST_NAME><LAST_NAME>Kriston</LAST_NAME><EMAIL_1>l.kriston@uke.uni-hamburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medical Psychology</DEPARTMENT><ORGANISATION>University Medical Center, Hamburg - Eppendorf</ORGANISATION><ADDRESS_1>Martinistrasse 52</ADDRESS_1><CITY>Hamburg</CITY><ZIP>20246</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><FAX_1>+ 49 40 7410 54965</FAX_1></ADDRESS></PERSON><PERSON ID="12341" ROLE="AUTHOR"><FIRST_NAME>Karla</FIRST_NAME><LAST_NAME>Soares-Weiser</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>CEO</POSITION><EMAIL_1>karla@enhance-reviews.com</EMAIL_1><EMAIL_2>ksoaresweiser@gmail.com</EMAIL_2><URL>www.enhance-reviews.com</URL><ADDRESS><ORGANISATION>Enhance Reviews Ltd</ORGANISATION><ADDRESS_1>Central Office, Cobweb Buildings</ADDRESS_1><ADDRESS_2>The Lane, Lyford</ADDRESS_2><CITY>Wantage</CITY><ZIP>OX12 0EE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 589687</PHONE_1></ADDRESS></PERSON><PERSON ID="32829627489460063558100414114554" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Nicola</FIRST_NAME><LAST_NAME>Maayan</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>Nicola@enhance-reviews.com</EMAIL_1><ADDRESS><ORGANISATION>Enhance Reviews Ltd</ORGANISATION><ADDRESS_1>Central Office, Cobweb Buildings</ADDRESS_1><ADDRESS_2>The Lane, Lyford</ADDRESS_2><CITY>Wantage</CITY><ZIP>OX12 0EE</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 589 687</PHONE_1></ADDRESS></PERSON><PERSON ID="E1682DE482E26AA201DAB7D8016E5C44" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Berner</LAST_NAME><EMAIL_1>dr.m.berner@rhein-jura-klinik.de</EMAIL_1><EMAIL_2>berner@nz.ukl.uni-freiburg.de</EMAIL_2><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>Rhein-Jura Klinik</ORGANISATION><ADDRESS_1>Schneckenhalde 13</ADDRESS_1><CITY>Bad Säckingen</CITY><ZIP>D-79713</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-10-09 13:43:32 +0100" MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="12" MONTH="9" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="4" MONTH="11" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-09-12 11:33:46 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-09-12 11:33:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>Update completed, additional trials added but no change to overall conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-12 11:32:56 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>New search May 2012, new studies added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-05-23 13:07:26 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-23 13:07:26 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="3" YEAR="2009"/>
<DESCRIPTION>
<P>Change to new format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-23 13:07:25 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-05-23 13:07:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Contact Author details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Freiburg University Medical Center</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-10-17 10:54:21 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="Bethany  L York">
<TITLE MODIFIED="2012-09-24 15:21:35 +0100" MODIFIED_BY="Bethany  L York">Management of sexual problems due to antipsychotic drug therapy</TITLE>
<SUMMARY_BODY MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>Drugs commonly used to treat schizophrenia often cause sexual problems.This may affect erection, lubrication, orgasm, desire or libido, ejaculation, sexual arousal or overall sexual satisfaction. This may have serious negative consequences such as putting people off taking their medication or stopping taking drugs at an early stage. Sexual problems may limit a person&#8217;s quality of life, worsen self-esteem and cause relationship problems.Strategies to manage these sexual problems are taking additional drugs (Viagra <SUP>TM</SUP>), short drug holidays when people temporarily stop antipsychotic medication, reduction of dose and switching to another antipsychotic drug. This review includes four pioneering studies with a total of 138 participants lasting between two weeks to four months, meaning all were small and quite short. Two of the studies compared the effects of drugs to treat sexual problems and two compared the effect of switching to a different antipsychotic drug (while remaining on a current antipsychotic). There is some evidence that sildenafil ((Viagra<SUP>TM</SUP>, Revatio<SUP>TM</SUP>)) may be a good treatment for men who have problems getting and maintaining an erection. It also seems to increase frequency and satisfaction of sexual intercourse. Switching to olanzapine may improve sexual functioning in men and women.</P>
<P>However, before confident claims can be made, much more research on strategies to deal with sexual problems should be undertaken. Sildenafil may be a useful option in the treatment of sexual problems in men with schizophrenia, but this conclusion is based only on one small, short trial. Switching to olanzapine may improve sexual functioning in men and women, but the trial assessing this was small. Further well designed trials and research, which investigate the effects of dose reduction, drug holidays, taking drugs such as Viagra <SUP>TM</SUP>, and switching antipsychotic medication, are much needed.</P>
<P>This plain language summary (PLS) was written by a consumer contributor, Ben Gray from RETHINK: Benjamin Gray, Service User and Service User Expert, Rethink Mental Illness, Email: <A HREF="mailto:ben.gray@rethink.org">ben.gray@rethink.org</A>.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-10-09 13:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>Psychotropic drugs are associated with sexual dysfunction. Symptoms may concern penile erection, lubrication, orgasm, libido, retrograde ejaculation, sexual arousal, or overall sexual satisfaction. These are major aspects of tolerability and can highly affect patients&#8217; compliance.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of different strategies (e.g. dose reduction, drug holidays, adjunctive medication, switching to another drug) for treatment of sexual dysfunction due to antipsychotic therapy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-10-09 13:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>An updated search was performed in the Cochrane Schizophrenia Group&#8217;s Trials Register (3 May 2012) and the references of all identified studies for further trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included all relevant randomised controlled trials involving people with schizophrenia and sexual dysfunction.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-10-09 13:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>We extracted data independently. For dichotomous data we calculated random effects risk ratios (RR) with 95% confidence intervals (CI), for crossover trials we calculated Odds Ratios (OR) with 95% CI. For continuous data, we calculated mean differences (MD) on the basis of a random-effects model. We analysed cross-over trials under consideration of correlation of paired measures.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-10-09 13:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>Currently this review includes four pioneering studies (total n = 138 , duration two weeks to four months), two of which are cross-over trials. One trial reported significantly more erections sufficient for penetration when receiving sildenafil compared with when receiving placebo (n = 32, MD 3.20 95% CI 1.83 to 4.57), a greater mean duration of erections (n = 32, MD 1.18 95% CI 0.52 to 1.84) and frequency of satisfactory intercourse (n = 32, MD 2.84 95% CI 1.61 to 4.07). The second trial found no evidence for selegiline as symptomatic treatment for antipsychotic-induced sexual dysfunction compared with placebo (n = 10, MD change on Aizenberg's sexual functioning scale -0.40 95% CI -3.95 to 3.15). No evidence was found for switching to quetiapine from risperidone to improve sexual functioning (n = 36, MD -2.02 95% CI -5.79 to 1.75). One trial reported significant improvement in sexual functioning when participants switched from risperidone or an typical antipsychotic to olanzapine (n = 54, MD -0.80 95% CI -1.55 to -0.05).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>We are not confident that cross-over studies are appropriate for this participant group as they are best for conditions that are stable and for interventions with no physiological and psychological carry-over. Sildenafil may be a useful option in the treatment of antipsychotic-induced sexual dysfunction in men with schizophrenia, but this conclusion is based only on one small short trial. Switching to olanzapine may improve sexual functioning in men and women, but the trial assessing this was a small, open label trial. Further well designed randomised control trials that are blinded and well conducted and reported, which investigate the effects of dose reduction, drug holidays, symptomatic therapy and switching antipsychotic on sexual function in people with antipsychotic-induced sexual dysfunction are urgently needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-10-11 14:50:53 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>Sexual dysfunction is an important public health problem that affects the overall well-being of many people with schizophrenia (<LINK REF="REF-El-Kissi-2011" TYPE="REFERENCE">El Kissi 2011</LINK>; <LINK REF="REF-Laumann-1999" TYPE="REFERENCE">Laumann 1999</LINK>; <LINK REF="REF-Nicolaou-2012" TYPE="REFERENCE">Nicolaou 2012</LINK>). It is well established that psychotropic drugs commonly cause sexual dysfunction (<LINK REF="REF-El-Kissi-2011" TYPE="REFERENCE">El Kissi 2011</LINK>; <LINK REF="REF-Kelly-2004" TYPE="REFERENCE">Kelly 2004</LINK>; <LINK REF="REF-Montejo-2010" TYPE="REFERENCE">Montejo 2010</LINK>; <LINK REF="REF-_x00dc__x00e7_ok-2007" TYPE="REFERENCE">Üçok 2007</LINK>; <LINK REF="REF-Zemishlany-2012" TYPE="REFERENCE">Zemishlany 2012</LINK>). Symptoms may include impairments of: penile erection, lubrication, orgasm, libido, retrograde ejaculation, sexual arousal or overall sexual satisfaction. This adverse effect has been reported to occur with many classes of psychotropic medications though incidences vary in the reported literature between the different agents and countries (<LINK REF="REF-Kelly-2004" TYPE="REFERENCE">Kelly 2004</LINK>; <LINK REF="REF-Malik-2007" TYPE="REFERENCE">Malik 2007</LINK>; <LINK REF="REF-Xiang-2011" TYPE="REFERENCE">Xiang 2011</LINK>). As an example, the identical drug was reported to have an incidence of sexual dysfunction of 8% in one trial (<LINK REF="REF-Herman-1990" TYPE="REFERENCE">Herman 1990</LINK>) and 75% in another (<LINK REF="REF-Segraves-1998" TYPE="REFERENCE">Segraves 1998</LINK>). Sexual dysfunction has been described to be associated with antipsychotic-agents to a great extent (<LINK REF="REF-El-Kissi-2011" TYPE="REFERENCE">El Kissi 2011</LINK>; <LINK REF="REF-Montejo-2010" TYPE="REFERENCE">Montejo 2010</LINK>). Psychotropic-induced sexual dysfunction may have serious negative consequences such as non-compliance with medication or early discontinuation of pharmacotherapy (<LINK REF="REF-Apantaku_x002d_Olajide-2011" TYPE="REFERENCE">Apantaku-Olajide 2011</LINK>; <LINK REF="REF-Hashimoto-2012a" TYPE="REFERENCE">Hashimoto 2012a</LINK>). Moreover, sexual dysfunctions may diminish a person&#8217;s quality of life, worsen self-esteem and cause relationship problems (<LINK REF="REF-Althof-2005" TYPE="REFERENCE">Althof 2005</LINK>; <LINK REF="REF-Laumann-1999" TYPE="REFERENCE">Laumann 1999</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-08-24 13:29:00 +0100" MODIFIED_BY="[Empty name]">
<P>Different strategies to treat psychotropic-induced sexual dysfunction have been considered including drug holidays, dose reduction, switching to another psychotropic drug that is meant to be less likely to cause sexual dysfunction and a large number of agents for symptomatic therapy (<LINK REF="REF-Clayton-1998" TYPE="REFERENCE">Clayton 1998</LINK>; <LINK REF="REF-Gitlin-1994" TYPE="REFERENCE">Gitlin 1994</LINK>; <LINK REF="REF-Kelly-2004" TYPE="REFERENCE">Kelly 2004</LINK>; <LINK REF="REF-Nicolaou-2012" TYPE="REFERENCE">Nicolaou 2012</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>Dose reduction means reducing the dose of the agent causing the sexual dysfunction. A special form of dose reduction is the intervention of drug holidays; this involves discontinuation of the drug two to three days before the anticipated sexual activity. After the sexual activity, the patient can either ignore the skipped medication and carry on with the usual dose or make up for all, or part of the unused medication. Agents that can be used symptomatically to reverse sexual dysfunction induced by psychotropic medication include psychostimulant agents such as PDE-5 (phosphodiesterase type 5) inhibitors (i.e. sildenafil) and yohimbine (<LINK REF="REF-Clayton-1998" TYPE="REFERENCE">Clayton 1998</LINK>; <LINK REF="REF-Kelly-2004" TYPE="REFERENCE">Kelly 2004</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>While for many agents, such as antidepressants, the problem of sexual adverse effects has been the focus of concern for years (<LINK REF="REF-Clayton-2006" TYPE="REFERENCE">Clayton 2006</LINK>; <LINK REF="REF-Williams-2006" TYPE="REFERENCE">Williams 2006</LINK>), there is little information about the effects of different strategies in treating antipsychotic-induced sexual dysfunction</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the effects of different strategies (dose reduction, drug holidays, symptomatic therapy, switching to another antipsychotic) for treatment of sexual dysfunction due to antipsychotic therapy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-10-11 14:50:53 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-10-11 14:50:53 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-06-28 11:12:01 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials. If a trial was described as 'double blind' but implied randomisation, we included such trials in a sensitivity analysis (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=19282831132975366559120322160711&amp;format=REVMAN#SENSITIVITY_ANALYSIS">Sensitivity analysis</A>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion resulted in statistically significant differences, we did not add the data from these lower quality studies to the results of the better trials, but presented such data within a subcategory. We excluded quasi-randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments, we only included data if the adjunct treatment was evenly distributed between groups and it was only the strategy for the treatment of sexual dysfunction that was randomised.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>We included trials that involved both men and women, of any age, suffering from sexual dysfunction due to antipsychotics in any aspect of sexual performance or behaviour (e.g. penile erection, lubrication, orgasm, libido, sexual arousal or overall sexual satisfaction) <I>as <U>measured by criteria defined by the primary authors of the trial</U>
</I>
<U>s</U>.</P>
<P>We considered the following antipsychotic drugs as potential causes of sexual dysfunction: alimemazine, amisulpride, benperidol, bromperidol, chlorprothixene, clopenthixol, clozapine, dixyrazine, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, melperone, olanzapine, perazine, perphenazine, pimozide, pipamperone, promazine, promethazine, prothipendyl, quetiapine, reserpine, risperidone, sulpiride, thioridazine, trifluperazine, trifluperidol, triflupromazine, ziprasidone, zotepine, zuclopenthixol.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Dose reduction</HEADING>
<P>Reduction of the dose of the agent causing the sexual dysfunction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Drug holidays</HEADING>
<P>Discontinuation of the drug two to three days before the anticipated sexual activity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Adjunctive therapy</HEADING>
<P>Use of additional therapy specifically targeted to improve sexual dysfunction symptoms, for example, sildenafil.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Switching to another antipsychotic drug</HEADING>
<P>To reduce any sexual adverse effects of a specific compound or compounds.</P>
<P>All the above techniques could be compared with each other or placebo, no intervention (untreated control groups) or maintenance intervention.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-10-11 14:50:53 +0100" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks) categories.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-09-18 14:00:35 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. No clinically significant improvement of sexual dysfunction as defined by the authors, e.g. less than 50% improvement on a rating scale</HEADING>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-10-11 14:50:53 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Improvement of sexual dysfunction</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">1.1 Objective assessment of improvement of sexual dysfunction by the trialists</HEADING>
<P>1.1.1 Clinically significant improvement of sexual dysfunction as defined by the authors<BR/>1.1.2 Average score/change of sexual dysfunction</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">1.2 Subjective assessment of improvement of sexual dysfunction by the participants</HEADING>
<P>1.2.1 Clinically significant improvement of sexual dysfunction as defined by the authors - other than long term<BR/>1.2.2 Average score/change of sexual dysfunction</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Leaving the study early (for any reason e.g. adverse events or inefficacy of treatment)</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Quality of life</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">3.1 Improvement of quality of life - as defined by each of the studies</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.2 Average score/change of quality of life</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Adverse outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">4.1 Death</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.2 Other specific adverse effects e.g. worsening of psychotic symptoms</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3 Non specific side effects</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Economic data</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">5.1 Direct costs</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">5.2 Indirect costs</HEADING>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. 'Summary of findings' table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2008" TYPE="REFERENCE">Schünemann 2008</LINK>) and used the <A HREF="http://www.ims.cochrane.org/revman/gradepro">GRADE</A> profiler to import data from Review Manager (<A HREF="http://www.ims.cochrane.org/revman">RevMan</A>) to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient-care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1. Sexual function</HEADING>
<P>1.1 Objective assessment of sexual dysfunction as defined by each of the studies<BR/>1.2 Subjective assessment of sexual dysfunction as defined by each of the studies</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Leaving the study early</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Quality of life</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Adverse effects</HEADING>
<P>4.1 Death<BR/>4.2 Psychotic symptoms<BR/>4.3 Extrapyramidal symptoms</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-10-10 13:49:14 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-10-10 13:49:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Cochrane Schizophrenia Group Trials Register (May 2012)</B>
</P>
<P>For details of previous searches please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We updated this search. The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (3 May 2012).</P>
<P>[*sexual dys* in title or abstract of REFERENCE or in health care conditions of STUDY]<BR/>
<BR/>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to relevant existing or new review titles.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-09-18 14:01:22 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Personal contact and pharmaceutical companies</HEADING>
<P>For the update, we did not contact the first author of each included study or companies involved in the production of the principal antipsychotic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Reference searching</HEADING>
<P>We inspected the reference lists of all identified studies for additional studies.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-10-10 14:13:15 +0100" MODIFIED_BY="[Empty name]">
<P>Methods used in data collection and analysis for this update are described below; for methods used in previous versions, please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<STUDY_SELECTION MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, review authors MB and MH independently inspected citations from the new electronic search and identified relevant abstracts. The same two review authors inspected full articles of the abstracts meeting inclusion criteria and carried out the reliability check of all citations from the new electronic search.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-10 14:13:15 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>For this update, Enhance Reviews authors (KSW and NM) extracted and analysed data from included studies. We extracted data presented only in graphs and figures whenever possible. When further information was necessary, we contacted authors of studies in order to obtain missing data or for clarification.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the instrument has not been developed or modified by one of the trialists for that particular trial.</P>
<P>Ideally, instruments should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we have noted whether or not this is the case in <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint), which can be difficult in unstable and difficult to measure conditions such as schizophrenia. We decided primarily to use endpoint data, and only use change data if the former were not available. We would have combined endpoint and change data in the analysis had there been data to combine, as we used mean differences (MD) rather than standardised mean differences (SMD) throughout (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion:<BR/>a) standard deviations (SD) and means are reported in the paper or obtainable from the authors;<BR/>b) when a scale starts from the finite number zero, the SD, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>));<BR/>c) if a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) which can have values from 30 to 210), we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD&gt;(S-S min), where S is the mean score and S min is the minimum score.<BR/>
<BR/>Endpoint scores on scales often have a finite start and end point and these rules can be applied. We would have entered skewed endpoint data from studies of fewer than 200 participants in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at mean if the sample size is large; we would have entered skewed endpoint data from large trials into syntheses.</P>
<P>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not based solely on the mean and the SD. In these cases, we entered change data into the syntheses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>If relevant data were available, we would have made efforts to convert outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005" TYPE="REFERENCE">Leucht 2005</LINK>; <LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>). We assumed that a 50% reduction of a total score should also be a meaningful cut-off for other scales. If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for the strategy for the treatment of sexual dysfunction. Where keeping to this would have made it impossible to avoid outcome titles with clumsy double-negatives we would have reported data where the left of the line indicates an unfavourable outcome and noted this in the relevant graphs.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, two members of the Enhance Review team (KSW and NM) worked independently by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) to assess risk of bias in trials. This new set of criteria is based on evidence of associations between overestimation and a high risk of bias in the trial such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P>
<P>Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain additional information.</P>
<P>We have noted the level of risk of bias in both the text of the review and in the 'Summary of findings' tables.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-10-09 13:14:07 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes, we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI)*. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios (ORs) and that ORs tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). We did not calculate the Number Needed to Treat/Harm (NNT/H). The NNT/H statistic with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta-analyses and interpretation (<A HREF="http://archie.cochrane.org/sections/documents/view?version=10522344846093567587120911135455&amp;format=REVMAN#REF-Hutton-2009">Hutton 2009</A>). For binary data presented in the 'Summary of findings' table, where possible, we calculated illustrative comparative risks.</P>
<P>* For cross-over trials we calculated OR and its 95% confidence interval (CI) (See <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes we estimated mean difference (MD) between groups. We would prefer not to calculate standardised effect size measures (standardised mean difference (SMD)). However, had scales of considerable similarity been used, we would have presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. Authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Had there been cluster trials included and where clustering was not accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation coefficients (ICC) for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>For adjustment for clustering a posteriori, the binary data as presented in a report were divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed taking into account ICCs and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). Both effects are very likely in severe mental illness, and usually only data from the first phase of corss-over trials are used, however, we did use data from both phases of cross-over studies (see <LINK TAG="PRO_REV_DIFF" TYPE="SECTION">Differences between protocol and review</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>If a study had involved more than two treatment arms, if relevant, we would have presented the additional treatment arms in comparisons. If data had been binary we would simply have added these and combined them within the two-by-two table. If data were continuous we would have combined the data following the formula in section 7.7.3.8 (Combining groups) of the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If the additional treatment arms were not relevant, we would not have reproduced these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>At some degree of loss of follow-up, data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). In this review, we planned that should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would have marked such data with (*) to indicate that such a result may well be prone to bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>In the case where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once-randomised-always-analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed to have the same rates of negative outcome as those who completed, with the exception of the outcome of death and adverse effects. For these outcomes the rate of those who stay in the study - in that particular arm of the trial - was used for those who did not. If we had high attrition we would have undertaken a sensitivity analysis to test how prone the primary outcomes were to change when data only from people who complete the study to that point were compared with the intention-to-treat analysis using the above assumptions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>In the case where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported, we presented and used these data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either P value or T value available for differences in mean, we calculated them according to the rules described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>): When only the SE was reported, SDs were calculated by the formula SD = SE * square root (n). Chapters 7.7.3 and 16.1.3 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) present detailed formulae for estimating SDs from other statistics such as P values, T or F values, confidence intervals or ranges. If these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<LINK REF="REF-Leucht-2007" TYPE="REFERENCE">Leucht 2007</LINK>). Therefore, where LOCF data have been used in the trial, if less than 50% of the data have been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we fully discussed these.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2 </SUP>statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to systematic variation rather than due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). An I<SUP>2 </SUP>estimate greater than or equal to around 50% accompanied by a statistically significant Chi<SUP>2</SUP> statistic was interpreted as evidence of substantial heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). When substantial heterogeneity was found in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes as there were less than 10 included studies. In other cases, where funnel plots were meaningful, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the random-effects model for all analyses with the exception of <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Subgroup analyses - only primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Clinical state, stage or problem</HEADING>
<P>We proposed to undertake this review and provide an overview of the effects of strategies for the treatment of sexual dysfunction for people with schizophrenia in general. In addition, however, we tried to report data on subgroups of people in the same clinical state, stage and with similar problems. We were not able to undertake subgroup analyses based on these as there was only one study for each comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Investigation of heterogeneity</HEADING>
<P>Where heterogeneity was high, we have reported this. First, we investigated whether data had been entered correctly. Second, if data were correct, we planned to inspect the graph visually and to remove outliers to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, then we would not pool data but would discuss the issues. We know of no supporting research for this 10% cut-off, but we use prediction intervals as an alternative to this unsatisfactory state.</P>
</SUBSECTION>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-09-19 17:31:40 +0100" MODIFIED_BY="[Empty name]">
<P>We applied all sensitivity analyses to the primary outcome of this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way so as to imply randomisation. For the primary outcomes we would have included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have entered all data from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up and missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we would have compared the findings on primary outcomes when we used imputed compared to complete data only. If there was a substantial difference, we would have reported results and discussed them.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Risk of bias</HEADING>
<P>We would have analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we would have included data from these trials in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Imputed values</HEADING>
<P>We also planned to undertake a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials.</P>
<P>If we noted substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the trials in which imputed ICC was used with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>The updated search identified a total of 30 relevant studies. Two trials met all criteria for study selection for this review in addition to the two studies included in the last version of the review. Fifty studies have now been excluded, no studies are awaiting assessment and no ongoing studies have been identified.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>The current review includes eight reports describing four studies (<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>; <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>; <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>; <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK>) including a total of 138 participants with schizophrenia or delusional disorder.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Methods</HEADING>
<P>We included two cross-over studies (<LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK>; <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>) and two parallel studies (<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>; <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>) All studies were stated to be randomised. Three of the studies were double blind, <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> was not blinded.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Length of trials</HEADING>
<P>Three studies presented data on 'short-term' follow-up: two weeks (<LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>), three weeks (<LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK>) and six weeks (<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>); <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> had a follow-up of four months.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Participants</HEADING>
<P>All studies included people with formally operationalised diagnoses. In one study people with schizophrenia were included (<LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK>), in two studies people with schizoaffective disorder were also included (<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>; <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>), as diagnosed by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (<LINK REF="REF-DSM_x002d_IV" TYPE="REFERENCE">DSM-IV</LINK>). In <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>, participants with schizophrenia or delusional disorder were included, as diagnosed by the International Classification of Diseases, Tenth Revision (<LINK REF="REF-ICD_x002d_10" TYPE="REFERENCE">ICD-10</LINK>). In three studies (<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>; <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>; <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK>) participants with sexual dysfunction were included. In <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> the participants were included if they had hyperprolactinaemia (an abnormally high concentration of prolactin in the blood). The participants also all had moderate sexual dysfunction at baseline.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Setting</HEADING>
<P>
<LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> included both inpatients and outpatients; the other three studies included only outpatients. <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK> was conducted in the USA, <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> in India, <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> in Israel and <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> did not report the country.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Study size</HEADING>
<P>All studies were very small: <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK> included 42 participants, <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> included 32 participants, <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> included 54, and <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> included 10.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Intervention</HEADING>
<P>Two trials evaluated adjunctive medication to antipsychotic treatment. <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> evaluated 25-50 mg/day sildenafil against placebo and <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> 15 mg/day selegiline, also against placebo. Two trials evaluated switching from one antipsychotic to another: <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK> tested maintenance of risperidone versus switching from risperidone to quetiapine and <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> compared maintenance of risperidone or typical antipsychotic versus switching to olanzapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Outcomes</HEADING>
<P>The following outcomes were reported by the included studies: leaving the study early, sexual function (number of erections, mean duration of erections, improved erections, frequency of satisfactory intercourse, sexual functioning measured on the Arizona Sexual Experience Scale (ASEX), prolactin levels), adverse events (psychopathology, extrapyramidal symptoms).</P>
<P>The following outcomes were not reported by any of the studies: objective assessment of improvement of sexual dysfunction by the trialists, clinically significant improvement of sexual dysfunction as defined by the authors, quality of life, death, non-specific side effects, economic outcomes (costs of therapy).</P>
<SUBSECTION>
<HEADING LEVEL="5">7.1 Outcome scales</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">7.1.1 Sexual dysfunction</HEADING>
<P>i. Patient log data<BR/>This standardised diary is filled out by the patient over the study period. Data are then extracted by investigators. The outcomes were:<BR/>
</P>
<UL>
<LI>number of erections sufficient for penetration;</LI>
<LI>mean duration of erections, and</LI>
<LI>frequency of satisfactory intercourse.</LI>
</UL>
<P>
<LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> reported these outcomes in this way.</P>
<P>ii. Aizenberg`s sexual functioning scale (ASF) (<LINK REF="REF-Aizenberg-1997" TYPE="REFERENCE">Aizenberg 1997</LINK>)<BR/>This scale assesses improvement from baseline. In this instrument patients assess their sexual dysfunction with regard to four domains of sexual activity: desire, erection, ejaculation, and satisfaction from sexual performance. Each item is rated in comparison to pre-treatment function on a four-point scale (from 'markedly decreased' to 'unchanged or normal'). A total score is calculated by summing the four domain scores. <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> employed this scale.</P>
<P>iii. General Efficacy Questionnaire (GEQ) (<LINK REF="REF-Goldstein-1998" TYPE="REFERENCE">Goldstein 1998</LINK>)<BR/>This was used by <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>. In this instrument general dichotomous (yes/no) questions are used to assess general treatment efficacy. The most frequently used question of this instrument is "Did the treatment improved your erection?". The questions of interest in the included study were:<BR/>
</P>
<UL>
<LI>if medication improved erections, and</LI>
<LI>if they would take medication in the future if it was available.</LI>
</UL>
<P>iv. Arizona Sexual Experience Scale (ASEX) (<LINK REF="REF-McGahuey-2000" TYPE="REFERENCE">McGahuey 2000</LINK>)<BR/>This is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from five to 30, with the higher scores indicating more pronounced sexual dysfunction. This scale was used by <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>.</P>
<P>v. Global Impressions of Sexual Function (GISF) (<LINK REF="REF-Michelson-2001" TYPE="REFERENCE">Michelson 2001</LINK>)<BR/>This is a patient-rated scale that measures the patient&#8217;s subjective feelings toward their sexual function. The report consists of four items covering sexual interest/desire, arousal (erection for men and vaginal lubrication for women), climax and overall sexual function. Each item is rated from 1 = Normal to 5 = Severely impaired. This scale was used by <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.1.2 Adverse effects - Psychopathology</HEADING>
<P>i. Positive and Negative Syndrome Scale (PANSS) (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>
<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>, <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> and <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> used this to measure exacerbations of psychotic symptoms. This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from one, absent to seven, extreme. It can be divided into three sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity.</P>
<P>ii. Clinical Global Impression Scale (CGI) (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is used to assess both severity of illness and clinical improvement, by comparing the conditions of the person standardised against other people with the same diagnosis. A seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement. CGI-Severity (CGI-S) is one component of the CGI, which rates illness severity.</P>
<P>iii. Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from zero to six or one to seven. Scores can range from zero to 126, with high scores indicating more severe symptoms.</P>
<P>iv. Mini-Mental State Examation (MMSE) (<LINK REF="REF-Folstein-1975" TYPE="REFERENCE">Folstein 1975</LINK>)<BR/>This is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. This scale was used by <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">7.1.3 Adverse effects - extrapyramidal symptoms</HEADING>
<P>i. Simpson-Angus Scale (SAS) (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>)<BR/>This scale was employed to measure extrapyramidal symptoms. The 10-item SAS is used to evaluate the presence and severity of parkinsonian symptomatology and other extrapyramidal effects. Higher scores reflect more adverse effects. This scale was used by <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>.</P>
<P>ii. Barnes Akathisia Scale (<LINK REF="REF-Barnes-1989" TYPE="REFERENCE">Barnes 1989</LINK>)<BR/>This is a 12-item scale consisting of a standardised examination followed by questions rating the orofacial, extremity and trunk movements, as well as three global measurements. Each of these 10 items can be scored from zero (none) to four (severe). Two additional items assess the dental status. The AIMS ranges from zero to 40, with higher scores indicating greater severity. This scale was used by <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>.</P>
<P>iii. Abnormal Involuntary Movement Scale (AIMS) (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>This is a 12-item clinician-rated scale to assess severity of dyskinesias (specifically, orofacial movements and extremity and truncal movements) in patients taking neuroleptic medications. Items are scored on a zero (none) to four (severe) basis; the scale provides a total score (items one through seven) or item eight can be used in isolation as an indication of overall severity of symptoms. This scale was used by <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty studies have now been excluded. Twenty-seven were excluded as they were not randomised, most of which were observational studies or case-reports. A further 23 studies were excluded as the participants did not have sexual dysfunction.</P>
<SUBSECTION>
<HEADING LEVEL="3">Awaiting assessment</HEADING>
<P>No studies are currently awaiting assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>We identified no ongoing studies.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>See also <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>With regard to random sequence generation and allocation concealment, risk of bias was rated low in one study (<LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>), in the remaining studies risk of bias was unclear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies (<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>; <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK>; <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK>) were described as double blind; risk of bias was low in <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK> and unclear in the other two studies; blinding of outcome assessors led to a low risk of bias in <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> and risk of bias remained unclear in the other two studies. <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> was an open label study and rated as high risk of bias for blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-09-19 17:43:39 +0100" MODIFIED_BY="[Empty name]">
<P>All studies were at low risk of bias regarding incomplete outcome data.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies were at low risk of bias with regard to selective reporting. <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK> was rated as being at high risk of bias due to missing observations on the outcome without giving reasons and prolactin levels were reported only in a sub-sample of participants.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>Two studies <LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK>; <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>) were rated as being at high risk of other bias. In <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> the risk of bias was low, and in <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> it was unclear.</P>
<P>A major flaw of <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> is that reported test statistics (paired t test) do not correspond to reported P values. A detailed examination suggests that t values are reported falsely (ten times higher due to a possible decimal point placement error).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-10-09 13:14:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">COMPARISON 1. ADJUNCTIVE TREATMENT - SPECIFIC: SILDENAFIL versus PLACEBO</HEADING>
<P>
<LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> (n = 32) compared sildenafil with placebo as additional medication to antipsychotic treatment in a cross-over trial with two weeks follow-up. The results were only presented with both phases combined so it was not possible to present only the results from the first phase.</P>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Objective assessment of improvement of sexual dysfunction</HEADING>
<P>In patient logs, participants reported statistically significantly more erections that were sufficient for penetration when receiving sildenafil compared with those allocated placebo (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; n = 31, mean difference (MD) 3.20 95% confidence interval (CI) 1.83 to 4.57). Statistically significant differences favouring sildenafil were also found concerning mean scores relating to duration of erections (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; n = 31, MD 1.18 95% CI 0.52 to 1.84) and frequency of satisfactory intercourse (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; n = 31, MD 2.84 95% CI 1.61 to 4.07).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Subjective assessment of improvement of sexual dysfunction</HEADING>
<P>Participants were more satisfied with sildenafil than with placebo: statistically significantly more participants answered the questions "Has the treatment improved your erections?" (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>; n = 31, odds ratio (OR) 11.76 95% CI 6.54 to 21.13) and "Would you take the drug in future if it were available?" (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; n = 31, OR 2.50 95% CI 1.48 to 4.22) with 'yes` when receiving sildenafil.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.3 Leaving the study early</HEADING>
<P>One participant in the placebo group withdrew consent immediately after randomisation. We found no statistically significant difference between treatment and control group concerning leaving the study early after two weeks follow-up (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>; n = 32, risk ratio (RR) 0.33 95% CI 0.01 to 7.62).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">COMPARISON 2. ADJUNCTIVE TREATMENT - NON-SPECIFIC: SELEGILINE versus PLACEBO</HEADING>
<P>
<LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> compared selegiline with placebo in a small (n = 10) cross-over trial, with three weeks follow-up. The results were only presented with both phases combined so it was not possible to present only the results from the first phase.</P>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Objective assessment of improvement of sexual dysfunction</HEADING>
<P>Sexual function change from baseline measured on the Aizenberg's sexual functioning scale after three weeks follow-up did not differ significantly between selegiline and placebo phases (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>; n = 10, MD -0.40 95% CI -3.95 to 3.15).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Leaving the study early</HEADING>
<P>No participants left the study in any phase (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Adverse effects</HEADING>
<P>No significant difference was found between selegiline and placebo phases regarding extrapyramidal symptoms after three weeks follow-up measured on the Simpson-Angus scale (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; n = 10, MD -0.90 95% CI -3.88 to 2.08) and psychotic symptoms measured on the PANSS (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; n = 10, MD 0.50 95% CI -0.61 to 1.61).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">COMPARISON 3. SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE versus MAINTENANCE RISPERIDONE</HEADING>
<P>
<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK> (n = 42) compared switching from risperidone to quetiapine with maintenance risperidone, with six weeks follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Subjective assessment of improvement of sexual dysfunction</HEADING>
<P>No statistically significant difference was found between treatment groups in the improvement of sexual dysfunction as measured on the ASEX scale with six weeks follow-up (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; n = 36, MD -2.02 95% CI -5.79 to 1.75).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Surrogate assessment of improvement of sexual dysfunction</HEADING>
<P>Prolactin levels were measured in a sub-sample of participants. A significant difference was found in favour of the treatment group after six weeks follow-up (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; n = 17, MD -13.60 95% CI -25.76 to -1.44).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Leaving the study early</HEADING>
<P>No participants were reported as leaving the study early, however, four participants in the intervention group and two in the control group had missing observations for the primary outcome at the end of the trial, although there was no statistically significant difference found between the treatment groups (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>; n = 42, RR 2.20 95% CI 0.45 to 10.74).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.4 Adverse effects</HEADING>
<P>No statistically significant difference was found between switching to quetiapine and maintenance risperidone regarding psychotic symptoms measured on the PANSS scale after six weeks follow-up (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; n = 42, MD -0.60 95% CI -4.35 to 3.15).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">COMPARISON 4. SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE versus MAINTENANCE OF RISPERIDONE/FGA (First Generation Antipsychotic)</HEADING>
<P>
<LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK> (n = 54) compared switching from risperidone to quetiapine with maintenance of risperidone or typical antipsychotic, with four months follow-up.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Subjective assessment of improvement of sexual dysfunction</HEADING>
<P>A statistically significant difference was found in the improvement of sexual dysfunction measured on the GISF scale in favour of switching to olanzapine after four months follow-up (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; n = 54, MD -0.80 95% CI -1.55 to -0.05). This result is a product of last observation carried forward assumptions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Surrogate assessment of improvement of sexual dysfunction</HEADING>
<P>A statistically significant difference was found in prolactin levels in favour of the treatment group after four months follow-up (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; n = 54, MD -30.84, 95% CI -47.46 to -14.22). This result is a product of last observation carried forward assumptions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3 Leaving the study early</HEADING>
<P>Nine participants in the switch to olanzapine group and four in the maintenance group left the study early and there was no statistically significant difference between the treatment groups (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>; n = 54, RR 0.25 95% CI 0.79 to 6.43).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Adverse effects</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">4.4.1 Psychopathology</HEADING>
<P>No statistically significant difference was found between switching to olanzapine and maintenance risperidone or typical antipsychotic regarding psychotic symptoms over four months measured on the PANSS scale (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; n = 41, MD 0.20 95% CI -6.93 to 7.33), the BPRS scale (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>; n = 41, MD -0.30 95% CI -4.57 to 3.97), the CGI-severity scale (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>; n = 41, MD -0.10 95% CI -0.59 to 0.39) and the MMSE scale (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>; n = 41, MD 0.0 95% CI -1.35 to 1.35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.4.2 Extrapyramidal symptoms</HEADING>
<P>Extrapyramidal symptoms were measured on three scales, no statistically significant difference was found between the treatment groups on any of the scales after four months follow-up: the Barnes Akathisia Scale (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>; n = 41, MD -0.10 95% CI -0.63 to 0.43), the Simpson-Agnus Scale (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>; n = 41, MD -0.90, 95% CI -2.25 to 0.45), or the AIMS scale (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>; n = 41, MD -0.30 95% CI -1.19 to 0.59).<BR/>
<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Four studies are included in this review: two estimate the effects of drugs compared against placebo to treat sexual dysfunction (<LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> and <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK>), and two compare the effect of switching to a different antipsychotic with maintaining current antipsychotic treatment (<LINK REF="STD-Byerly-2008" TYPE="STUDY">Byerly 2008</LINK> and <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>). All four studies were small and had a follow-up of less than four months. As each study investigated a different intervention it was not possible to undertake any meta-analysis.</P>
<SUMMARY_OF_RESULTS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">1. Adjunctive treatment - Specific: Sildenafil versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1 Sexual functioning</HEADING>
<P>There is limited evidence that sildenafil can improve antipsychotic-induced sexual dysfunction in men, increasing the number of erections sufficient for penetration, the mean duration of erections, and the frequency of satisfactory intercourse over the course of two weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2 Adverse effects</HEADING>
<P>This study did not report data on adverse effects. It is, therefore, impossible to tell how safe sildenafil is when added to antipsychotic drugs.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">2. Adjunctive treatment - Non-specific: Selegiline versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Sexual functioning</HEADING>
<P>A single very small, short study did not find selegiline to be superior to placebo in treating antipsychotic-induced sexual dysfunction in men after three weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Adverse effects</HEADING>
<P>No differences in extrapyramidal movement disorders and exacerbation of schizophrenic symptoms were found between selegiline and placebo after three weeks.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">3. Switching antipsychotic: to quetiapine versus maintenance of risperidone</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Sexual functioning</HEADING>
<P>Switching from risperidone to quetiapine did not improve sexual functioning in men and women when measured on the ASEX scale after six weeks. However, prolactin levels (a surrogate measure of sexual function) were significantly lower in a sub-sample of patients who had switched to quetiapine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Adverse effects</HEADING>
<P>No difference in the severity of schizophrenic symptoms was found between patients who switched to quetiapine or remained on risperidone after six weeks.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">4. Switching antipsychotic: to olanzapine versus maintenance of risperidone/typical antipsychotic</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">4.1 Sexual functioning</HEADING>
<P>Male and female patients who switched to olanzapine showed improved sexual functioning after four months measured on the GISF scale and reduced prolactin levels (a surrogate measure of sexual function) compared with patients remaining on risperidone or typical antipsychotic.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.2 Adverse effects</HEADING>
<P>No difference was found in schizophrenic symptoms or extrapyramidal symptoms between patients switching to olanzapine or remaining on risperidone or typical antipsychotic after four months.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>The two studies that focused on adjunctive therapies included only male participants. The intervention in <LINK REF="STD-Gopalakrishnan-2006" TYPE="STUDY">Gopalakrishnan 2006</LINK> was sildenafil, a drug typically prescribed to men to treat erectile dysfunction, which was the focus of the study. However, the intervention in <LINK REF="STD-Kodesh-2003" TYPE="STUDY">Kodesh 2003</LINK> was selegine, a drug used as an antiparkinsonian medication. Both studies had very short follow-up periods (two and three weeks) and were very small cross-over studies. It is presumable that such methods are inappropriate for evaluation of sexual dysfunction. Cross-over studies are suitable for the evaluation of treatments for short-term symptoms without carry-over effects. Whether sexual dysfunction can be considered acute and drug treatments as free from carry-over effects, remains questionable</P>
<P>The two studies that focused on switching antipsychotic included both male and female participants, but were also small studies. Although the follow-up periods were slightly longer (six weeks to four months) they still do not allow long-term outcome measures to be assessed.</P>
<P>The trials were conducted in India, Israel and the USA, but there is no indication that sexual problems differ by region or race (<LINK REF="REF-Tharyan-2006" TYPE="REFERENCE">Tharyan 2006</LINK>), therefore, if the results were more authoritative they could be widely applicable. No studies reported on quality of life or the economic aspects of treating sexual dysfunction.</P>
<P>We did not identify any trialsinvestigating other strategies for treating sexual dysfunction in people taking antipsychotics - drug holidays and reducing the dose of antipsychotic.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of the current evidence is very low based on GRADE. The limited number of studies, the small number of participants, the inclusion of only men in two of the studies, and two studies being cross-over trials are the main methodological limitations to the quality of the evidence. One trial had a high risk of bias for selective reporting of outcomes. With regard to sequence generation, allocation concealment, blinding and selective reporting, the remaining studies were considered to be at a low or unclear risk of bias. Three of the studies were very short in duration (two to six weeks); one study was of moderate duration (four months) but was an open label trial.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-09-20 08:22:39 +0100" MODIFIED_BY="[Empty name]">
<P>The extensive search was planned to be highly sensitive, however, we may have failed to identify some relevant studies.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-07-05 10:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>No other reviews covering the same topic are available to compare their results with those obtained from this review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-09-20 08:32:32 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. For people with schizophrenia and sexual dysfunction</HEADING>
<P>For men with schizophrenia taking antipsychotic medication and experiencing erectile dysfunction as an adverse effect of the pharmacological treatment, sildenafil may be a useful treatment option as additional medication. Men should be aware that this conclusion is based on limited data and that long-term effects are unknown. Drug-drug interactions may be a problem and sildenafil is contraindicated in certain instances, particularly in people on concurrent nitrates (<LINK REF="REF-Tharyan-2006" TYPE="REFERENCE">Tharyan 2006</LINK>).Men and women with antipsychotic-induced sexual dysfunction caused by risperidone or typical antipsychotic may find that switching to olanzapine improves their sexual functioning. Both men and women with both schizophrenia and sexual dysfunction could reasonably request that their treatment, whatever that may be, should be undertaken only in the context of a randomised study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. For clinicians</HEADING>
<P>Sildenafil may be a useful option to improve erectile functioning in the treatment of antipsychotic-induced erectile dysfunction in men with schizophrenia, and switching to olanzapine from risperidone or typical antipsychotic may be useful in managing sexual dysfunction in men and women. However, although the studies in this review are pioneering they are far too small and short to be the source of robust evidence. Clinicians will continue treatment, based on sources other than trials, until they feel that such levels of evidence are inadequate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. For managers/policy makers</HEADING>
<P>For people facing cost-effectiveness and cost-utility decisions, currently, there is no useful trial-based data to support decision making.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. General</HEADING>
<P>The four trials in this review were mostly well reported but future studies should ensure that they comply with the CONSORT statement (<LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Specific</HEADING>
<P>Randomised controlled trials are needed to provide evidence for the effects of different strategies (dose reduction, drug holidays, symptomatic treatment, switching) to manage sexual adverse events in patients receiving antipsychotic medication.</P>
<P>These studies should focus also on other dysfunctions such as erectile dysfunction and include both men and women who experience antipsychotic-induced sexual dysfunction. All outcomes should be investigated on the short, medium as well as long term and adverse effects should be reported in detail. Data on quality of life, partner satisfaction with the intervention, and economic outcomes should be included. We suggest an outline of such a study in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-07-05 10:12:13 +0100" MODIFIED_BY="[Empty name]">
<P>The reviewers would like to thank the Cochrane Schizophrenia Group for supporting this review. The Cochrane Schizophrenia Group maintains and provides a template for the methods section of their reviews. We have used and adapted this. Enhance Reviews Ltd provided support in completing this update.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-10-17 10:54:21 +0100" MODIFIED_BY="[Empty name]">
<P>Michael Berner - has received tuition fees from Pfizer, Germany, manufacturer of the PDE V-inhibitor Sildenafil and tuition fees from Astra Zeneca, Germany, manufacturer of  the antipsychotic agent quetiapine.</P>
<P>All other review authors: none.<BR/>
<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-10-10 14:03:33 +0100" MODIFIED_BY="[Empty name]">
<P>Hannah Schmidt - interpretation of the results, preparation of full review (2012 Update).</P>
<P>Mathias Hagen - development of the search strategy and literature search (original review).</P>
<P>Levente Kriston - data extraction and analysis (original review), review of statistical analysis (Update 2012), interpretation of the results, preparation of full review.</P>
<P>Karla Soares-Weiser - data extraction and analysis, risk of bias assessment, write up of results (2012 Update).</P>
<P>Nicola Maayan - data extraction and analysis, risk of bias assessment, write up of results (2012 Update).</P>
<P>Michael Berner - protocol preparation, development of the search strategy, data analysis (original review), interpretation of the results, preparation of full review.<BR/>
</P>
<P> </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Cross-over trials (amendment to original protocol)</HEADING>
<P>Because, within cross-over studies, intervention and control group measures are correlated, paired analyses, accounting for this correlation, was needed (apart from attrition rates, as participants can leave the study only once). For continuous outcomes, mean differences can be calculated. For these studies we reported dichotomous outcomes as odds ratios. This is because odds ratios rather than risk ratios are proposed for cross-over trials (<LINK REF="REF-Curtin-2002b" TYPE="REFERENCE">Curtin 2002b</LINK>). All analyses were based on the recommendations by <LINK REF="REF-Curtin-2002a" TYPE="REFERENCE">Curtin 2002a</LINK> and <LINK REF="REF-Curtin-2002b" TYPE="REFERENCE">Curtin 2002b</LINK>. We used the generic inverse variance method to enable individually optimised strategy for each study. In the main we calculated standard error of estimates from exactly reported t or P statistics.</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>The protocol was amended after publication to include methods for statistical analysis of cross-over trials</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-09 13:19:28 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-10-09 13:18:26 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-10-09 13:16:22 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-2008" MODIFIED="2012-10-09 13:16:22 +0100" MODIFIED_BY="[Empty name]" NAME="Byerly 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-09 13:16:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Byerly M J, Nakonezny P, Bugno R, Boles J</AU>
<TI>A randomized, double-blind pilot trial of switching to quetiapine vs. risperidone continuation in outpatients with risperidone-associated sexual dysfunction</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-24 13:27:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Byerly MJ, Nakonezny PA, Rush AJ</AU>
<TI>Sexual functioning associated with quetiapine switch vs risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial</TI>
<SO>Psychiatry Research</SO>
<YR>2008</YR>
<VL>159</VL>
<PG>115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-17 13:47:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byerly MJ, Nakonezny PA</AU>
<TI>A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic</TI>
<SO>Clinical Schizophrenia and Related Psychoses</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>209-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-24 13:28:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakonezny PA, Byerly MJ, Rush AJ</AU>
<TI>The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs quetiapine</TI>
<SO>Journal of Sex and Marital Therapy</SO>
<YR>2007</YR>
<VL>33</VL>
<PG>203-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gopalakrishnan-2006" MODIFIED="2012-10-04 14:56:39 +0100" MODIFIED_BY="Heather Maxwell" NAME="Gopalakrishnan 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-04 14:56:39 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gopalakrishnan R, Jacob KS, Kuruvilla A, Vasantharaj B, John JK</AU>
<TI>Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2006</YR>
<VL>163</VL>
<NO>3</NO>
<PG>494-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2006" MODIFIED="2012-09-24 13:29:06 +0100" MODIFIED_BY="[Empty name]" NAME="Kinon 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-17 13:47:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA</AU>
<TI>Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>577-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-24 13:29:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kinon BJ, Liu H, Ahl J</AU>
<TI>Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels</TI>
<SO>Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kodesh-2003" MODIFIED="2012-10-04 14:57:26 +0100" MODIFIED_BY="Heather Maxwell" NAME="Kodesh 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-10-04 14:57:26 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kodesh A, Weizman A, Aizenberg D, Hermesh H, Gelkopf M, Zemishlany Z</AU>
<TI>Selegiline in the treatment of sexual dysfunction in schizophrenic patinets maintained on neuroleptics: a pilot study</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>4</NO>
<PG>193-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-10-09 13:18:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aizenberg-1995" NAME="Aizenberg 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aizenberg D, Zemishlany Z, Dorfman-Ettrog P, Weizman A</AU>
<TI>Sexual dysfunction in male schizophrenic patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<PG>137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aizenberg-1996" NAME="Aizenberg 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aizenberg D, Shiloh R, Zemishlany Z, Weizman A</AU>
<TI>Low-dose imipramine for thioridazine-induced male orgasmic disorder</TI>
<SO>Journal of Sex &amp; Marital Therapy</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>3</NO>
<PG>225-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atmaca-2002" NAME="Atmaca 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Atmaca M, Kuloglu M, Tezcan E</AU>
<TI>Sildenafil use in patients with olanzapine-induced erectile dysfunction</TI>
<SO>International Journal of Impotence Research</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>6</NO>
<PG>547-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aviv-2004" NAME="Aviv 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aviv A, Shelef A, Weizman A</AU>
<TI>An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<NO>1</NO>
<PG>97-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bastecky-1980" MODIFIED="2012-09-24 13:30:21 +0100" MODIFIED_BY="[Empty name]" NAME="Bastecky 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-09-24 13:30:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bastecky J, Kalvach Z, Halkova E, Tosovsky J</AU>
<TI>High doses of clorotepin in chronic schizophrenia (preliminary report)</TI>
<SO>Agressologie</SO>
<YR>1980</YR>
<VL>21</VL>
<NO>A</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benatov-1999" MODIFIED="2012-10-09 13:16:39 +0100" MODIFIED_BY="Heather Maxwell" NAME="Benatov 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-10-09 13:16:39 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benatov R, Reznik I, Zemishlany Z</AU>
<TI>Sildenafil citrate (Viagra) treatment of sexual dysfunction in a schizophrenic patient</TI>
<SO>European Psychiatry</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>353-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuzen-2007" MODIFIED="2012-09-24 13:30:53 +0100" MODIFIED_BY="[Empty name]" NAME="Beuzen 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-09-24 13:30:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beuzen JN, L'Italien G, Hanssens L, Marcus RN, mcquade RD, Carson WH</AU>
<TI>Changes in prolactin levels and arizona sexual experience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the schizophrenia trial of aripiprazole (STAR) study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<PG>421-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blin-1996" NAME="Blin 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blin O, Azorin JM, Bouhours P</AU>
<TI>Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>1</NO>
<PG>38-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruggeman-2002" MODIFIED="2012-09-24 13:31:22 +0100" MODIFIED_BY="[Empty name]" NAME="Bruggeman 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-24 13:31:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruggeman R, Knegtering H, Castelein S, Van Der Linde J, Bous J</AU>
<TI>Risperidone versus quetiapine: preliminary results of a comparative study on sexual dysfunctioning and prolactin elevation</TI>
<SO>Nordic Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Byerly-2004" MODIFIED="2012-10-09 13:16:50 +0100" MODIFIED_BY="Heather Maxwell" NAME="Byerly 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-10-09 13:16:50 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Byerly M, Lescouflair E, Weber M, Bugno R, Fisher R, Carmody T, et al</AU>
<TI>An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction</TI>
<SO>Journal of Sex &amp; Marital Therapy</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>5</NO>
<PG>325-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claghorn-1987" MODIFIED="2012-10-09 13:16:58 +0100" MODIFIED_BY="Heather Maxwell" NAME="Claghorn 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-10-09 13:16:58 +0100" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, et al</AU>
<TI>The risks and benefits of clozapine versus chlorpromazine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>6</NO>
<PG>377-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Correa-1987" NAME="Correa 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Correa N, Opler LA, Kay SR, Birmaher B</AU>
<TI>Amantadine in the treatment of neuroendocrine side effects of neuroleptics</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<NO>2</NO>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costa-2007" MODIFIED="2012-06-06 14:06:09 +0100" MODIFIED_BY="[Empty name]" NAME="Costa 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-06-06 14:06:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costa AMN, De Lima MS, Faria M, Filho SR, De Oliveira IR, De Jesus MJ</AU>
<TI>A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>2</NO>
<PG>165-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Covington-2000" NAME="Covington 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Covington L, Cola PA</AU>
<TI>Clozapine vs. haloperidol: antipsychotic effects on sexual function in schizophrenia</TI>
<SO>Sexuality and Disability</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>1</NO>
<PG>41-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Boer-2011" MODIFIED="2012-09-24 13:34:27 +0100" MODIFIED_BY="[Empty name]" NAME="De Boer 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-09-24 13:34:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Boer MK, Wiersma D, Bous J, Sytema S, Van der Moolen AEGM, Wilffert B, et al</AU>
<TI>A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (ras study)</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<PG>523-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Degen-1982" NAME="Degen 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Degen K</AU>
<TI>Sexual dysfunction in women using major tranquilizers</TI>
<SO>Psychosomatics</SO>
<YR>1982</YR>
<VL>23</VL>
<NO>9</NO>
<PG>959-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dufresene-1988" MODIFIED="2012-09-24 13:36:07 +0100" MODIFIED_BY="[Empty name]" NAME="Dufresene 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-09-24 13:36:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dufresene RL, Kass DJ, Becker RE</AU>
<TI>Bupropion and thiothixene versus placebo and thiothixene in the treatment of depression in schizophrenia</TI>
<SO>Drug Development Research</SO>
<YR>1988</YR>
<VL>12</VL>
<NO>259</NO>
<PG>266</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hanssens-2008" MODIFIED="2012-09-24 13:36:29 +0100" MODIFIED_BY="[Empty name]" NAME="Hanssens 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-09-24 13:36:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hanssens L, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W</AU>
<TI>The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)</TI>
<SO>BMC Psychiatry</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoyberg-1993" NAME="Hoyberg 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M</AU>
<TI>Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1993</YR>
<VL>88</VL>
<PG>395-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2008" MODIFIED="2012-10-09 13:17:15 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-09 13:17:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang ZY, Li PC</AU>
<TI>Effects of olanzapine, risperidone and chlorpromazine on prolactin and erectile function in male patients with schizophrenia</TI>
<SO>Modern Medicine and Health [&#29616;&#20195;&#21307;&#33647;&#21355;&#29983;]</SO>
<YR>2008</YR>
<VL>24</VL>
<PG>2077-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaneda-2001" NAME="Kaneda 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaneda Y</AU>
<TI>Effects of risperidone on gonadal axis hormones in schizophrenia</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2001</YR>
<VL>35</VL>
<PG>1523-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keller-2002" NAME="Keller 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keller R, Mongini F</AU>
<TI>Switch to quetiapine in antipsychotic agent-related hyperprolactinemia</TI>
<SO>Neurological Sciences</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>5</NO>
<PG>233-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2006" MODIFIED="2012-06-06 14:08:19 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-06 14:08:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kelly DL, Conley RR</AU>
<TI>A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>340-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2002" NAME="Kim 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim K-S, Pae C-U, Chae J-H, Bahk W-M, Jun T-Y, Kim D-J, Dickson RA</AU>
<TI>Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>5</NO>
<PG>408-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kleinberg-1999" NAME="Kleinberg 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M</AU>
<TI>Prolactin-levels and adverse events in patients treated with risperidone</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>1</NO>
<PG>57-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knegtering-2000" MODIFIED="2012-10-09 13:17:27 +0100" MODIFIED_BY="[Empty name]" NAME="Knegtering 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-09-24 13:37:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Knegtering R, Boks M, Wiersma D, Blijd C, Bruggeman R, Oer RBV</AU>
<TI>Sexual dysfunctions in patients on antipsychotics</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-24 13:38:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Knegtering R, Boks M, Wiersma D, Blijd C, Bruggeman R, Van Oer RB</AU>
<TI>Sexual dysfunctions in patients on antipsychotics</TI>
<SO>Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-07 10:46:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, et al</AU>
<TI>A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>56-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-09 13:17:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Knegtering R, Castelein S, Bous H, Van der Linde J, Bruggeman R, Kluiter H, et al</AU>
<TI>A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning</TI>
<SO>Proceedings of the Bi-annual Winter Workshop on Schizophrenia Research; 2002 Feb 24 - Mar 1; Davos, Switzerland</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knegtering-2002a" MODIFIED="2012-10-09 13:17:42 +0100" MODIFIED_BY="[Empty name]" NAME="Knegtering 2002a" YEAR="2002">
<REFERENCE MODIFIED="2012-10-09 13:17:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knegtering H, Castelein S, Linde J Van-der, Bous J</AU>
<TI>Sexual dysfunctions and serum prolactin levels in patients using risperidone or quetiapine: a randomised trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>163</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knegtering-2006" MODIFIED="2012-10-09 13:17:52 +0100" MODIFIED_BY="[Empty name]" NAME="Knegtering 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-09 13:17:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knegtering H, Boks M, Blijd C, Castelein S, Van Den Bosch RJ, Wiersma D</AU>
<TI>A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning</TI>
<SO>Journal of Sex and Marital Therapy</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>4</NO>
<PG>315-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kockott-1996" NAME="Kockott 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kockott G, Pfeiffer W</AU>
<TI>Sexual disorders in nonacute psychiatric outpatients</TI>
<SO>Comprehensive Psychiatry</SO>
<YR>1996</YR>
<VL>37</VL>
<NO>1</NO>
<PG>56-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kubacki-1984" MODIFIED="2012-09-24 13:39:27 +0100" MODIFIED_BY="[Empty name]" NAME="Kubacki 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-09-24 13:39:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kubacki A, Bathurst NB</AU>
<TI>Sexual disinhibition and antipsychotics</TI>
<SO>Nova Scotia Medical Bulletin</SO>
<YR>1984</YR>
<VL>6</VL>
<PG>81-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmoud-2011" MODIFIED="2012-10-09 13:18:05 +0100" MODIFIED_BY="[Empty name]" NAME="Mahmoud 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-10-09 13:18:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Mahmoud A, Hayhurst KP, Drake RJ, Lewis SW</AU>
<TI>Second generation antipsychotics improve sexual dysfunction in schizophrenia: A randomised controlled trial</TI>
<SO>Schizophrenia Research and Treatment</SO>
<YR>2011:596898. Epub 2011 Jan 16</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-24 13:41:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mahmoud A, Hayhurst KP, Lewis SW</AU>
<TI>Antipsychotic drugs and sexual dysfunctions</TI>
<SO>Proceedings of the 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-17 13:45:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmoud A, Hayhurst KP, Lewis SW</AU>
<TI>Antipsychotic drugs and sexual function</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>67</VL>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malik-2011" MODIFIED="2012-09-24 13:41:42 +0100" MODIFIED_BY="[Empty name]" NAME="Malik 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-09-24 13:41:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malik P, Kemmler G, Hummer M, Riecher-Roessler A, Kahn RS, Fleischhacker WW, et al</AU>
<TI>Sexual dysfunction in first-episode schizophrenia patients results from european first episode schizophrenia trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2011</YR>
<VL>31</VL>
<PG>274-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuoka-1986" MODIFIED="2012-09-24 13:41:54 +0100" MODIFIED_BY="[Empty name]" NAME="Matsuoka 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-09-24 13:41:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G</AU>
<TI>Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence</TI>
<SO>Japanese Journal of Psychiatry and Neurology</SO>
<YR>1986</YR>
<VL>40</VL>
<NO>4</NO>
<PG>639-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCreadie-1988" MODIFIED="2012-09-24 13:43:00 +0100" MODIFIED_BY="[Empty name]" NAME="McCreadie 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-09-24 13:43:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCreadie RG, Todd N, Livingston M, Eccleston D, Watt JAG, Tait D, et al</AU>
<TI>A double-blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1988</YR>
<VL>78</VL>
<PG>49-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mir-2006" MODIFIED="2012-10-09 13:18:26 +0100" MODIFIED_BY="[Empty name]" NAME="Mir 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-10-09 13:18:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Mir A, Shivakumar K, Mcallister V, O Keane V, Mccrone P, Aitchinson KJ</AU>
<TI>Change in sexual dysfunction on switching to aripiprazole</TI>
<SO>Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-09 13:18:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mir A, Shivakumar K, Williamson RJ, Mcallister V, O'Keane V, Aitchison KJ</AU>
<TI>Change in sexual dysfunction with aripiprazole: A switching or add-on study</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>244-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mullen-2001" NAME="Mullen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mullen B, Brar JS, Vagnucci AH, Ganguli R</AU>
<TI>Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone</TI>
<SO>Schizophrenia Research</SO>
<YR>2001</YR>
<VL>48</VL>
<PG>155-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenberg-2001" MODIFIED="2012-10-04 15:28:48 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenberg 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-10-04 15:28:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Rosenberg K P, Bleiberg K, Kocsis J H</AU>
<TI>Psychotropic-induced sexual dysfunction among outpatients</TI>
<SO>Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-09-24 13:45:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rosenberg KP, Bleiberg K, Kocsis JH</AU>
<TI>Psychotropic-induced sexual dysfunction among outpatients</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<CY>Philadelphia, Pennsylvania, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sechter-2002" MODIFIED="2012-09-24 13:45:30 +0100" MODIFIED_BY="[Empty name]" NAME="Sechter 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-09-24 13:45:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y</AU>
<TI>Amisulpride versus risperidone in chronic schizophrenia: results of a 6-month double-blind study</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>6</NO>
<PG>1071-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Segraves-1999" NAME="Segraves 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Segraves RT</AU>
<TI>Two additional uses for sildenafil in psychiatric patients</TI>
<SO>Journal of Sex &amp; Marital Therapy</SO>
<YR>1999</YR>
<VL>25</VL>
<PG>265-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsai-2000" NAME="Tsai 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsai S-J, Hong C-J</AU>
<TI>Haloperidol-induced impotence improved by switching to olanzapine</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>5</NO>
<PG>391-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valevski-1998" NAME="Valevski 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valevski A, Modai I, Zbarski E, Zemishlany Z, Weizman A</AU>
<TI>Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>6</NO>
<PG>355-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wesby-1996" NAME="Wesby 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wesby R, Bullmore E, Earle J, Heavey A</AU>
<TI>A survey of psychosexual arousability in male patients on depot neuroleptic medication</TI>
<SO>European Psychiatry</SO>
<YR>1996</YR>
<VL>11</VL>
<PG>81-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wirshing-1999" MODIFIED="2012-09-24 13:46:19 +0100" MODIFIED_BY="[Empty name]" NAME="Wirshing 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-09-24 13:46:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wirshing DA, Perkins V, Marder SR, Wirshing WC</AU>
<TI>Sexual side effects of atypical antipsychotic medications</TI>
<SO>Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2002" MODIFIED="2012-06-17 11:34:41 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-06-17 11:34:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang X, Pang L, Huang Y</AU>
<TI>Sexual dysfunction of 220 schizophrenics</TI>
<SO>Health Psychology Journal</SO>
<YR>2002</YR>
<VL>10</VL>
<PG>247-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5468__x4e91_-2009" MODIFIED="2012-09-24 13:48:21 +0100" MODIFIED_BY="[Empty name]" NAME="&#21608;&#20113; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-09-24 13:48:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21608;&#20113;</AU>
<TI>Hydrogen benzene that clozapine induced salivation Immunotherapy Clinical [Google Translate]</TI>
<TO>&#27682;&#33519;&#37027;&#25935;&#27835;&#30103;&#27695;&#27694;&#24179;&#25152;&#33268;&#30340;&#27969;&#28046;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>2</NO>
<PG>132-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x4e1c__x536b_-2008" MODIFIED="2012-09-24 13:49:22 +0100" MODIFIED_BY="[Empty name]" NAME="&#24352;&#19996;&#21355; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-09-24 13:49:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#19996;&#21355;, &#29976;&#26223;&#26792;, &#39640;&#23384;&#21451;, &#27573;&#24800;&#23792;</AU>
<TI>A pilot study on the sexual hormones level of male patients with schizophrenia</TI>
<TO>&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#23545;&#30007;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#24615;&#28608;&#32032;&#27700;&#24179;&#30340;&#24433;&#21709;</TO>
<SO>&#23454;&#29992;&#21307;&#33647;&#26434;&#24535;</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1117-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8096__x6500__x6500_-2009" MODIFIED="2012-09-24 13:50:14 +0100" MODIFIED_BY="[Empty name]" NAME="&#32918;&#25856;&#25856; 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-09-24 13:50:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#32918;&#25856;&#25856;, &#26519;&#20255;&#25104;, &#23435;&#23425;, &#39640;&#38215;&#26494;</AU>
<TI>Effect of quetiapine on PRL secretion and sexual function of male schizophrenic patients</TI>
<TO>&#21945;&#30827;&#24179;&#23545;&#30007;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20652;&#20083;&#32032;&#21450;&#24615;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>8</NO>
<PG>897-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8c22__x65b0__x5e74_-2008" MODIFIED="2012-09-24 13:51:54 +0100" MODIFIED_BY="[Empty name]" NAME="&#35874;&#26032;&#24180; 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-09-24 13:51:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#35874;&#26032;&#24180;, &#33298;&#20154;&#20061;, &#38054;&#26691;&#26691;</AU>
<TI>Aripiprazole and risperidone in the treatment of male schizophrenia efficacy and sexual function [Google translate]</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#21450;&#21033;&#22521;&#37230;&#27835;&#30103;&#30007;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#21450;&#23545;&#24615;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>Hunan Medical Journal</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>6</NO>
<PG>1111-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9773__x897f__x9f99_-2010" MODIFIED="2012-06-27 11:00:42 +0100" MODIFIED_BY="[Empty name]" NAME="&#38771;&#35199;&#40857; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-27 11:00:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#38771;&#35199;&#40857;</AU>
<TI>Aripiprazole on male sexual function in patients with schizophrenia study Google Translate</TI>
<SO>Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao]</SO>
<YR>2010</YR>
<VL>31</VL>
<NO>18</NO>
<PG>2883-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9ec4__x7cb1__x9554_-2010" MODIFIED="2012-09-24 13:52:17 +0100" MODIFIED_BY="[Empty name]" NAME="&#40644;&#31921;&#38228; 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-06-17 11:21:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#40644;&#31921;&#38228;, &#40857;&#27427;, &#29579;&#33260;&#33538;</AU>
<TI>Quetiapine and risperidone on sex hormone levels in patients with schizophrenia Google Translate</TI>
<SO>China Pharmaceuticals</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>13</NO>
<PG>20-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-06-27 11:00:42 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-10-09 13:19:28 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-10-09 13:18:47 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aizenberg-1997" NAME="Aizenberg 1997" TYPE="JOURNAL_ARTICLE">
<AU>Aizenberg D, Gur S, Zemishlany Z, Granek M, Jeczmien P, Weizman A</AU>
<TI>Mianserin, a 5-HT2a/c and alpha2 antagonist in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors</TI>
<SO>Clinical Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>30</VL>
<PG>210-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Althof-2005" MODIFIED="2012-10-09 13:18:47 +0100" MODIFIED_BY="[Empty name]" NAME="Althof 2005" TYPE="JOURNAL_ARTICLE">
<AU>Althof SE, Leiblum SR, Chevret-Measson M, Hartmann U, Levine SB, McCabe M, et al</AU>
<TI>Psychological and interpersonal dimensions of sexual function and dysfunction</TI>
<SO>Journal of Sexual Medicine</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>6</NO>
<PG>793-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<NO>7066</NO>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Apantaku_x002d_Olajide-2011" MODIFIED="2012-09-24 13:53:40 +0100" MODIFIED_BY="[Empty name]" NAME="Apantaku-Olajide 2011" TYPE="JOURNAL_ARTICLE">
<AU>Apantaku-Olajide T, Gibbons P, Higgins A</AU>
<TI>Drug-induced sexual dysfunction and mental health patients' attitude to psychotropic medications</TI>
<SO>Sexual &amp; Relationship Therapy</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>2</NO>
<PG>145-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1989" MODIFIED="2012-09-24 13:54:09 +0100" MODIFIED_BY="[Empty name]" NAME="Barnes 1989" TYPE="JOURNAL_ARTICLE">
<AU>Barnes TR</AU>
<TI>A rating scale for drug-induced akathisia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>154</VL>
<PG>672-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2012-09-24 13:54:29 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<TO>Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite</TO>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS MODIFIED="2012-05-23 12:13:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10667106"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1983" MODIFIED="2012-09-24 13:54:38 +0100" MODIFIED_BY="[Empty name]" NAME="Chalmers 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers TC, Celano P, Sacks HS, Smith HJr</AU>
<TI>Bias in treatment assignment in controlled clinical trials</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>22</NO>
<PG>1358-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clayton-1998" NAME="Clayton 1998" TYPE="JOURNAL_ARTICLE">
<AU>Clayton DO, Shen WW</AU>
<TI>Psychotropic drug-induced sexual dysfunction</TI>
<SO>Drug Safety</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>4</NO>
<PG>299-312</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clayton-2006" NAME="Clayton 2006" TYPE="JOURNAL_ARTICLE">
<AU>Clayton A, Keller A, McGarvey EL</AU>
<TI>Burden of phase-specific sexual dysfunction with SSRIs</TI>
<SO>Journal of Affective Disorders</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002a" NAME="Curtin 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Altman DG, Elbourne D</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2131-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtin-2002b" NAME="Curtin 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Curtin F, Elbourne D, Altman DG</AU>
<TI>Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2145-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town</SO>
<YR>2000</YR>
<PB>The Cochrane Collaboration</PB>
<CY>Cape Town</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM_x002d_IV" MODIFIED="2012-09-24 13:55:26 +0100" MODIFIED_BY="[Empty name]" NAME="DSM-IV" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)</SO>
<YR>1994</YR>
<EN>4th</EN>
<PB>American Psychiatric Association</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Kissi-2011" MODIFIED="2012-09-24 13:56:34 +0100" MODIFIED_BY="[Empty name]" NAME="El Kissi 2011" TYPE="OTHER">
<AU>El Kissi Y, Mannai J, Laroussi M, Gaabout S, Ayachi M, Hadj Ali B</AU>
<TI>P03-209 - Sexual function in untreated then treated schizophrenic patients: a prospective study</TI>
<SO>European Psychiatry</SO>
<YR>2011</YR>
<VL>26</VL>
<PG>1378</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Folstein-1975" MODIFIED="2012-09-24 13:56:56 +0100" MODIFIED_BY="[Empty name]" NAME="Folstein 1975" TYPE="JOURNAL_ARTICLE">
<AU>Folstein MF, Folstein SE, McHugh PR</AU>
<TI>Mini mental state: a practical method for grading the cognitive state of patients for the clinician</TI>
<SO>Journal of Psychiatry Research</SO>
<YR>1975</YR>
<VL>12</VL>
<PG>189-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gitlin-1994" MODIFIED="2012-09-24 13:57:08 +0100" MODIFIED_BY="[Empty name]" NAME="Gitlin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gitlin MJ</AU>
<TI>Psychotropic medications and their effect on sexual function: diagnosis, biology and treatment approaches</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1994</YR>
<VL>55</VL>
<PG>406-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1998" NAME="Goldstein 1998" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA</AU>
<TI>Oral sildenafil in the treatment of erectile dysfunction</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>1397-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" MODIFIED="2012-09-24 13:57:33 +0100" MODIFIED_BY="[Empty name]" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the health survey for england 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2012-06-28 13:35:08 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hashimoto-2012a" MODIFIED="2012-09-24 13:57:55 +0100" MODIFIED_BY="[Empty name]" NAME="Hashimoto 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Hashimoto Y, Uno J, Miwa T, Kurihara M, Tanifuji H, Tensho M</AU>
<TI>Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients</TI>
<SO>Psychiatry &amp; Clinical Neurosciences</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>5</NO>
<PG>405-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herman-1990" NAME="Herman 1990" TYPE="JOURNAL_ARTICLE">
<AU>Herman JB, Brotman AW, Pollack MH, Falk WE</AU>
<TI>Fluoxetine-induced sexual dysfunction</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1990</YR>
<VL>51</VL>
<PG>25-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2012-09-24 14:00:39 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2005</YR>
<VL>2</VL>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-09-24 14:00:46 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICD_x002d_10" NAME="ICD-10" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The ICD-10 Classification of Mental and Behavioural Disorders</SO>
<YR>1992</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A, Opler LA</AU>
<TI>The Positive and Negative Syndrome Scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelly-2004" MODIFIED="2012-09-24 14:01:15 +0100" MODIFIED_BY="[Empty name]" NAME="Kelly 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kelly DL, Conley RR</AU>
<TI>Sexuality and schizophrenia: a review</TI>
<SO>Schizophrenia bulletin</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>4</NO>
<PG>767-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laumann-1999" NAME="Laumann 1999" TYPE="JOURNAL_ARTICLE">
<AU>Laumann EO, Paik A, Rosen RC</AU>
<TI>Sexual dysfunction in the United States: prevalence and predictors</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>6</NO>
<PG>537-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2012-05-23 12:13:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15982856"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of brief psychiatric rating scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2012-05-23 12:13:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16199797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2012-05-23 12:13:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16905632"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Malik-2007" MODIFIED="2012-09-24 14:01:47 +0100" MODIFIED_BY="[Empty name]" NAME="Malik 2007" TYPE="JOURNAL_ARTICLE">
<AU>Malik P</AU>
<TI>Sexual dysfunction in schizophrenia</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>2</NO>
<PG>138-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGahuey-2000" MODIFIED="2012-09-24 14:02:20 +0100" MODIFIED_BY="[Empty name]" NAME="McGahuey 2000" TYPE="JOURNAL_ARTICLE">
<AU>McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al</AU>
<TI>The Arizona Sexual Experience Scale (ASEX): reliability and validity</TI>
<SO>Journal of Sex and Marital Therapy</SO>
<YR>2000</YR>
<VL>26</VL>
<PG>25-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michelson-2001" MODIFIED="2012-09-24 14:02:41 +0100" MODIFIED_BY="[Empty name]" NAME="Michelson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Michelson D, Schmidt M, Lee J, Tepner R</AU>
<TI>Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment</TI>
<SO>Journal of Sex and Marital Therapy</SO>
<YR>2001</YR>
<VL>27</VL>
<PG>289-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2012-09-24 14:03:04 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c869</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montejo-2010" MODIFIED="2012-09-24 14:03:45 +0100" MODIFIED_BY="[Empty name]" NAME="Montejo 2010" TYPE="JOURNAL_ARTICLE">
<AU>Montejo ÁL, Majadas S, Rico-Villademoros F, LLorca G, De La Gándara J, Franco M, et al</AU>
<TI>Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics</TI>
<SO>Journal of Sexual Medicine</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>10</NO>
<PG>3404-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicolaou-2012" MODIFIED="2012-09-24 14:03:54 +0100" MODIFIED_BY="[Empty name]" NAME="Nicolaou 2012" TYPE="JOURNAL_ARTICLE">
<AU>Nicolaou L</AU>
<TI>Sexual dysfunction in people with schizophrenia</TI>
<SO>Mental Health Practice</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>10</NO>
<PG>20-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oxman-1992" NAME="Oxman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Oxman AD, Guyatt GH</AU>
<TI>A consumer's guide to subgroup analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>116</VL>
<NO>1</NO>
<PG>78-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schultz-1995" NAME="Schultz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schultz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2008" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2008" TYPE="BOOK_SECTION">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>359-83</PG>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Segraves-1998" MODIFIED="2012-09-24 14:04:27 +0100" MODIFIED_BY="[Empty name]" NAME="Segraves 1998" TYPE="JOURNAL_ARTICLE">
<AU>Segraves RT</AU>
<TI>Antidepressant-induced sexual dysfunction</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>Suppl 4</NO>
<PG>48-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" MODIFIED="2012-09-24 14:04:45 +0100" MODIFIED_BY="[Empty name]" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>212</VL>
<NO>Suppl</NO>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tharyan-2006" NAME="Tharyan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tharyan P, Gopalakrishan G</AU>
<TI>Erectile dysfunction</TI>
<SO>BMJ Clinical Evidence</SO>
<YR>2006</YR>
<VL>15</VL>
<PG>1227-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-2006" NAME="Williams 2006" TYPE="JOURNAL_ARTICLE">
<AU>Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM</AU>
<TI>Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey</TI>
<SO>Jounral of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2012-05-23 12:13:42 +0100" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xiang-2011" MODIFIED="2012-09-24 14:05:27 +0100" MODIFIED_BY="[Empty name]" NAME="Xiang 2011" TYPE="OTHER">
<AU>Xiang YT, Wang CY, Si TM, Lee EHM, He YL, Ungvari GS, et al</AU>
<TI>The low frequency of reported sexual dysfunction in Asian patients with schizophrenia (2001-2009): low occurrence or ignored side effect?</TI>
<SO>Human Psychopharmacology</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>4/5</NO>
<PG>352-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zemishlany-2012" MODIFIED="2012-09-24 14:05:37 +0100" MODIFIED_BY="[Empty name]" NAME="Zemishlany 2012" TYPE="OTHER">
<AU>Zemishlany Z</AU>
<TI>AS01-02 - The impact of psychiatric disorders on sexual dysfunction: an update</TI>
<SO>European Psychiatry</SO>
<YR>2012</YR>
<VL>27</VL>
<PG>1-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x00dc__x00e7_ok-2007" MODIFIED="2012-09-24 14:05:53 +0100" MODIFIED_BY="[Empty name]" NAME="Üçok 2007" TYPE="JOURNAL_ARTICLE">
<AU>Üçok A, &#304;ncesu C, Aker T, Erkoç &#350;</AU>
<TI>Sexual dysfunction in patients with schizophrenia on antipsychotic medication</TI>
<SO>European Psychiatry</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>5</NO>
<PG>328-33</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-10-09 13:19:28 +0100" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Berner-2006" NAME="Berner 2006" TYPE="JOURNAL_ARTICLE">
<AU>Berner MM, Hagen M, Kriston L</AU>
<TI>A systematic review of research on strategies for the management of antipsychotic-induced sexual dysfunction: high-level evidence is needed</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>10</NO>
<PG>1649-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berner-2007" MODIFIED="2012-10-09 13:19:28 +0100" MODIFIED_BY="Heather Maxwell" NAME="Berner 2007" TYPE="COCHRANE_REVIEW">
<AU>Berner MM, Hagen M, Kriston L, Omar H</AU>
<TI>Management of sexual dysfunction due to antipsychotic drug therapy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-10-04 14:44:34 +0100" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2012-10-04 14:44:34 +0100" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD003546.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2012-09-24 14:06:51 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Hashimoto-2012" MODIFIED="2012-09-24 14:06:51 +0100" MODIFIED_BY="[Empty name]" NAME="Hashimoto 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hashimoto Yasuhiko, Uno Junji, Miwa Takaichi, Kurihara Masaaki, Tanifuji Hiroaki, Tensho Masami</AU>
<TI>Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients</TI>
<SO>Psychiatry &amp; Clinical Neurosciences</SO>
<YR>2012</YR>
<VL>66</VL>
<NO>5</NO>
<PG>405-10</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Byerly-2008">
<CHAR_METHODS MODIFIED="2012-10-04 15:46:51 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Blinding: double blind.</P>
<P>Duration: 6 weeks.</P>
<P>Design: parallel, 1 week cross taper for patients randomised to quetiapine switch.</P>
<P>Setting: outpatients; USA.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: <LINK REF="REF-DSM_x002d_IV" TYPE="REFERENCE">DSM-IV</LINK> diagnosis of schizophrenia or schizoaffective disorder and risperidone-associated sexual dysfunction.<BR/>History: participants with schizoaffective disorder must have received a stable dose of antimanic and/or antidepressant medication for &#8805;30 days prior to study entry and have experienced stability of mood symptoms for &gt;2 weeks prior to baseline assessments. Written informed consent from patients was obtained.<BR/>N = 42.<BR/>Age: 24 to 58 years (mean 42.3 SD 9.6).<BR/>Sex: 22 men, 20 women.<BR/>Inclusion criteria: at least 18 years old, moderate sexual dysfunction (ASEX total score &#8805; 15), risperidone only antipsychotic &#8804; 4 mg/ day (unless history justified higher dose). Participants were excluded if they received a long-acting injectable antipsychotic within one dosing interval of intended study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-04 15:42:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Switching to quetiapine (to 300 mg/day week 1 and 2, 800 mg/day maximum allowable). N = 22.<BR/>2. Risperidone continuation (dose continued from pre-study, N = 20.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early</P>
<P>Sexual function (subjective assessment): ASEX</P>
<P>Sexual function (surrogate assessment): Prolactin levels (ng/mL)</P>
<P>Adverse effects: Psychopathology - PANSS<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-18 11:10:10 +0100" MODIFIED_BY="[Empty name]">
<P>Data were collected over a 3-year period from May 2002 to October 2005.</P>
<P>*Reported in a sub-sample of participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gopalakrishnan-2006">
<CHAR_METHODS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, using random-number table, concealed from investigators.<BR/>Blinding: double blind.<BR/>Duration: 2 weeks.<BR/>Design: monocentre, cross-over; no wash-out between treatment periods.</P>
<P>Setting: outpatients; India.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia or delusional disorder (<LINK REF="REF-ICD_x002d_10" TYPE="REFERENCE">ICD-10</LINK>) and antipsychotic-induced erectile dysfunction (<LINK REF="REF-DSM_x002d_IV" TYPE="REFERENCE">DSM-IV</LINK>).<BR/>History: informed consent obtained.<BR/>N = 32.<BR/>Age: between 20 and 45 (mean 35.1).<BR/>Sex: men.<BR/>Inclusion criteria: married and living with spouse; receiving antipsychotic medication (risperidone, olanzapine, clozapine or fluphenazine decanoate).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-04 15:45:20 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Sildenail: dose 25-50mg/day. N = 16.<BR/>2. Placebo. N = 16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-04 15:46:18 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Sexual function (objective assessment): number of erections sufficient for penetration, mean duration of erections, frequency of satisfactory intercourse.<BR/>Sexual function (subjective assessment):overall improvement and preference for taking the drug in future (GEQ).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kinon-2006">
<CHAR_METHODS MODIFIED="2012-07-09 10:46:06 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, strategy unknown.<BR/>Blinding: open label.<BR/>Duration: 4 months.<BR/>Design: parallel, multi-centre, 1 week cross taper for patients randomised to olanzapine switch.</P>
<P>Setting: inpatients and outpatients, country not reported.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia, schizophreniform or schizoaffective disorder (<LINK REF="REF-DSM_x002d_IV" TYPE="REFERENCE">DSM-IV</LINK>) and treatment-related hyperprolactinaemia.<BR/>History: not reported, written consent was obtained.<BR/>N = 54.<BR/>Age: between 18 and 71 (mean 39).<BR/>Sex: men and women.<BR/>Inclusion criteria: clinically stable, on conventional antipsychotics or risperidone at least 3 months prior to study entry.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-04 15:49:06 +0100" MODIFIED_BY="[Empty name]">
<P>1. Switching to olanzapine (day one 5 mg/day, increased to 10mg/day, adjusted in 5mg/day doses, range of 5-20mg/day). N = 27.<BR/>2. Remain on conventional antipsychotic or risperidone (current clinically stable dose) N = 27.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-04 15:49:57 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Sexual function (subjective assessment): Global Impressions of Sexual Function (GISF)*.</P>
<P>Sexual function (surrogate assessment): Serum prolactin level (ng/ml)* .<BR/>Adverse effects**: Psychopathology - PANSS, BPRS, CGI-Severity, MMSE.</P>
<P>Adverse effects**: Extrapyramidal symptoms - SAS (modified), BAS, AIMS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-04 15:50:20 +0100" MODIFIED_BY="[Empty name]">
<P>*Prolactin level and GISF were reported using the LOCF, N was not reported so we assumed this to be N = 27 in both groups.</P>
<P>**For the measures of adverse events N was not reported, so we assumed that N = 18 for the olanzapine group and N = 23 in the current treatment group, based on the reported losses to follow-up.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kodesh-2003">
<CHAR_METHODS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, strategy unknown.<BR/>Blinding: double blind.<BR/>Duration: 3 weeks.<BR/>Design: monocentre, cross-over; 2 weeks wash-out between treatment periods.</P>
<P>Setting: outpatients, Israel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (<LINK REF="REF-DSM_x002d_IV" TYPE="REFERENCE">DSM-IV</LINK>) and sexual dysfunction.<BR/>History: not reported, if informed consent was obtained.<BR/>N = 10.<BR/>Age: between 36 and 51 (mean 44.8).<BR/>Sex: men.<BR/>Inclusion criteria: receiving neuroleptic treatment (perphenazine or haloperidol), stable relationship with a female partner for at least 3 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-04 15:51:33 +0100" MODIFIED_BY="Heather Maxwell">
<P>1. Selegiline: dose 15 mg/day. N = 5.<BR/>2. Placebo. N = 5.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-09-13 08:49:49 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early.<BR/>Sexual function (objective assessment): ASF scale<BR/>Adverse effects: Psychopathology - PANSS</P>
<P>Adverse effects: Extrapyramidal symptoms - SAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-05 11:41:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;span modified=&quot;2012-07-05 13:16:00 +0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;not sure what this means&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-07-05 11:41:55 +0100" NOTES_MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>
<B>Scales</B>
<BR/>AIMS: Abnormal Involuntary Movement Scale<BR/>ASEX: Arizona Sexual Experiences Scale<BR/>ASF: Aizenberg`s sexual functioning scale<BR/>BAS: Barnes Akathisia Scale<BR/>BPRS: Brief Psychiatric Rating Scale<BR/>CG-I: Clinical Global Impression<BR/>DSM: Diagnostic and Statistical Manual<BR/>GEQ: General Efficacy Questionnaire<BR/>GISF: Global Impressions of Sexual Function<BR/>ICD: International Classification of Diseases<BR/>MMSE: Mini-Mental State Examination<BR/>PANSS: Positive and Negative Syndrome Scale<BR/>SAS: Simpson-Angus Scale</P>
<P>
<B>Other</B>
<BR/>LOCF: last observation carried forward<BR/>SD: standard deviation</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-10-04 15:40:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aizenberg-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aizenberg-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Atmaca-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aviv-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bastecky-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benatov-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:52:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuzen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:52:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with psychotic episode, not with sexual dysfunction.<BR/>Interventions: switched from risperidone to aripiprazole or standard of care.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Blin-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bruggeman-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with psychotic episode, not with sexual dysfunction. <BR/>Interventions: risperidone versus quetiapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Byerly-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Claghorn-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Correa-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-28 13:48:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Costa-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-28 13:48:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: conventional antipsychotics versus olanzapine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Covington-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, not with sexual dysfunction. <BR/>Interventions: clozapine versus haloperidol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:52:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Boer-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:52:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: aripiprazole versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Degen-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dufresene-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, not with sexual dysfunction. <BR/>Interventions: bupropion and thiothixene versus placebo and thiothixene.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:52:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hanssens-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.<BR/>Participants: people with psychotic episode, not with sexual dysfunction.<BR/>Interventions: aripiprazole versus standard of care (olanzapine, quetiapine or risperidone).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoyberg-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, not with sexual dysfunction. <BR/>Interventions: risperidone versus perphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:54:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:54:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: olanzapine versus risperidone versus chlorpromazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kaneda-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Keller-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:52:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kelly-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:52:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: risperidone versus quetiapine versus fluphenazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kim-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kleinberg-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:52:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knegtering-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:52:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: quetiapine versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:52:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knegtering-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:52:16 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: patients with a psychotic episode, no sexual dysfunction.</P>
<P>Interventions: quetiapine versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:52:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knegtering-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:52:10 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: olanzapine versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kockott-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kubacki-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:51:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mahmoud-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:51:54 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: first generation antipsychotics versus second generation antipsychotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:51:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malik-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:51:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: haloperidol versus amisulpride versus olanzapine versus quetiapine versus ziprasidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matsuoka-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCreadie-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, not with sexual dysfunction. <BR/>Interventions: remoxipride versus thioridazine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:51:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mir-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:51:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mullen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:51:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenberg-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:51:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sechter-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, not with sexual dysfunction. <BR/>Interventions: amisulpride versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Segraves-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsai-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Valevski-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wesby-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:51:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wirshing-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:51:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:47:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:47:44 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:47:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5468__x4e91_-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:47:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.<BR/>Interventions: ziprasidone versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:50:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x4e1c__x536b_-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:50:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised according hospital admission number.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.</P>
<P>Interventions: clozapine versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:51:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8096__x6500__x6500_-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:51:02 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.<BR/>Interventions: quetiapine versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 10:51:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8c22__x65b0__x5e74_-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 10:51:15 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.<BR/>Interventions: aripiprazole versus risperidone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 11:58:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9773__x897f__x9f99_-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 11:58:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.<BR/>Interventions: aripiprazole versus risperidone. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-27 11:01:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9ec4__x7cb1__x9554_-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-27 11:01:09 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised.</P>
<P>Participants: people with schizophrenia, not with sexual dysfunction.<BR/>Interventions: aripiprazole versus risperidone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-06-27 11:00:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-09-13 09:00:48 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-17 14:25:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>"Randomized", method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-06 16:59:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gopalakrishnan-2006">
<DESCRIPTION>
<P>Table of random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-17 14:42:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>"Randomized", method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-13 09:00:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kodesh-2003">
<DESCRIPTION>
<P>Randomly assigned, method of randomisation not detailed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-28 14:03:00 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-17 14:25:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 11:41:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gopalakrishnan-2006">
<DESCRIPTION>
<P>Concealed instructions opened at the time of random assignment, the research psychiatrists who executed the assignment of patients did not generate the assignment schedule. The allocation code was broken after data entry was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-17 14:42:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-28 14:03:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kodesh-2003">
<DESCRIPTION>
<P>Method of allocation not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-06-07 14:18:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-06-20 11:42:24 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-20 09:20:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>"Double blind". "Blinding to treatment group was maintained through the use of identical appearing capsules."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-20 11:41:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gopalakrishnan-2006">
<DESCRIPTION>
<P>Double blind.</P>
<P>&#8220;The sildenafil citrate and placebo capsules were identical.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-18 08:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>"Open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-06-20 11:42:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kodesh-2003">
<DESCRIPTION>
<P>&#8220;Double-blind&#8221;, method not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-28 14:02:58 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 09:17:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>ASEX: &#8220; study utilized self administered questionnaire cards that participants read silently to themselves. The participants then reported only the scale number that corresponded to their experience for each ASEX item&#8221;</P>
<P>PANSS: collection method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-20 11:41:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gopalakrishnan-2006">
<DESCRIPTION>
<P>&#8220;The research psychiatrists assessing outcome were blind to intervention status&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-18 08:15:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>"Open label".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-28 14:02:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kodesh-2003">
<DESCRIPTION>
<P>Method of outcome assessment not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-10-04 15:50:38 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-17 14:25:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>No losses to follow-up reported, but 2 missing observations for ASEX at 6 weeks in the risperidone group; 4 missing observations for ASEX at 6 weeks in the quetiapine group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-20 11:41:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gopalakrishnan-2006">
<DESCRIPTION>
<P>1 person withdrew consent after randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-04 15:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>9 losses to follow-up in the olanzapine group and 4 in the current treatment group. One patient in the olanzapine group and 3 patients in the non-switched group. Reasons for discontinuation were dyspnoea for the olanzapine-treated patient, and schizophrenia reaction (n = 2) and depression (n = 1) for the patients, who continued on pre-study therapy. Reasons for losses not reported for nine of the patients. LOCF used for the outcome sexual function measured on the GISF scale.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-06-28 14:02:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kodesh-2003">
<DESCRIPTION>
<P>No dropouts reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-10-04 15:51:56 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 09:23:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>All stated outcomes reported. </P>
<P>For ASEX there were missing observations and no reasons given for this. </P>
<P>Prolactin levels reported in a sub-sample of participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-04 15:46:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gopalakrishnan-2006">
<DESCRIPTION>
<P>Reported all stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-18 08:14:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>All stated outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-04 15:51:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kodesh-2003">
<DESCRIPTION>
<P>Reported all stated outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-17 14:25:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Byerly-2008">
<DESCRIPTION>
<P>Funded by NIMH K-Award grant # 5 K23 MH064930, the Stanley Medical Research Institute, the Betty Jo Hay Distinguished Chair in Mental Health, Mental Health Connections, a partnership between Dallas County Mental Health and Mental Retardation (MHMR) and the Department of Psychiatry of the University of Texas Southwestern Medical Center, and AstraZeneca LP. (ISS study number DIRUSQUET0186)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-20 11:41:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gopalakrishnan-2006">
<DESCRIPTION>
<P>Free of other biases. Funded by research grant 22F237 from Christian Medical College. The medication was provided by Sun Pharmaceuticals, which did not play any role in the design, conduct, analysis, or interpretation of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-17 14:56:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kinon-2006">
<DESCRIPTION>
<P>Funded by Eli Lilly and Company.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-09 13:14:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kodesh-2003">
<DESCRIPTION>
<P>Source of funding not reported. Reported t values do not correspond to reported P values.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-10-09 13:50:19 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-10-09 13:48:50 +0100" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-07-10 14:10:59 +0100" MODIFIED_BY="Grade Profiler">ADJUNCTIVE TREATMENT - SPECIFIC: SILDENAFIL versus PLACEBO for management of sexual dysfunction due to antipsychotic drug therapy</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>SILDENAFIL versus PLACEBO for management of sexual dysfunction due to antipsychotic drug therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with sexual dysfunction due to antipsychotic drug therapy<BR/>
<B>Settings:</B> Outpatients<BR/>
<B>Intervention:</B> SILDENAFIL versus PLACEBO<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SILDENAFIL versus PLACEBO</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Sexual function: Subjective assessment (number of erections)</B>
<BR/>Follow-up: 2 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean number of erections in the intervention groups was<BR/>
<B>3.2 higher</B>
<BR/>(1.83 to 4.57 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>31<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>This trial only included men.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Sexual function: Objective assessment (Global efficacy questionnaire, improved erections)</B>
<BR/>Follow-up: 2 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>OR 11.76 (6.54 to 21.13)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>31<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>OR calculated from the log of the odds ratio.This trial only included men.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Leaving the study early</B>
<BR/>Follow-up: 2 weeks</P>
</TD>
<TD>
<P>
<B>62 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>21 per 1000</B>
<BR/>(1 to 476)</P>
</TD>
<TD>
<P>
<B>RR 0.33 </B>
<BR/>(0.01 to 7.62)</P>
</TD>
<TD>
<P>32<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects: Death</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects: Psychotic symptoms</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects: Extrapyramidal symptoms</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Only one trial provided data for this comparison. It was a very small cross-over trial of short duration.<BR/>
<SUP>2</SUP> This trial only included men.<BR/>
<SUP>3</SUP> The 95% confidence intervals around the pooled effect estimate include both significant benefit and harm of intervention.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2012-10-09 13:49:24 +0100" MODIFIED_BY="Grade Profiler" NO="2" READONLY="YES">
<TITLE MODIFIED="2012-07-10 14:12:02 +0100" MODIFIED_BY="Grade Profiler">ADJUNCTIVE TREATMENT - NON-SPECIFIC: SELEGILINE versus PLACEBO for management of sexual dysfunction due to antipsychotic drug therapy</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>SELEGILINE versus PLACEBO for management of sexual dysfunction due to antipsychotic drug therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with sexual dysfunction due to antipsychotic drug therapy<BR/>
<B>Settings:</B> Outpatients<BR/>
<B>Intervention:</B> SELEGILINE versus PLACEBO<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SELEGILINE versus PLACEBO</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Sexual function: Subjective assessment (Aizenburg's scale)</B>
<BR/>Follow-up: 3 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean sexual function in the intervention groups was<BR/>
<B>0.4 lower</B>
<BR/>(3.95 lower to 3.15 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>0<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Leaving the study early</B>
<BR/>Follow-up: 3 weeks</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>10<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>Only one trial provided data for this comparison. No attritions were reported in this trial.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects: Death</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: Psychopathology (PANSS)</B>
<BR/>Follow-up: 3 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean psychopathology in the intervention groups was<BR/>
<B>0.50 higher</B>
<BR/>(0.61 lower to 1.61 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>10<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal symptoms (Simpson-Angus)</B>
<BR/>Follow-up: 3 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean extrapyramidal symptoms in the intervention groups was<BR/>
<B>0.9 lower</B>
<BR/>(3.88 lower to 2.08 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>10<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Only one trial provided data for this comparison. It was a very small cross-over trial of short duration. The risk of bias for random sequence generation, allocation concealment and blinding were unclear.<BR/>
<SUP>2</SUP> This trial only included men.<BR/>
<SUP>3</SUP> The 95% confidence intervals around the pooled effect estimate include both significant benefit and harm of intervention.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2012-10-09 13:50:06 +0100" MODIFIED_BY="Grade Profiler" NO="3" READONLY="YES">
<TITLE MODIFIED="2012-07-10 14:15:33 +0100" MODIFIED_BY="Grade Profiler">SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE versus MAINTENANCE RISPERIDONE for management of sexual dysfunction due to antipsychotic drug therapy</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>SWITCH to quetiapine versus MAINTENANCE risperidone for management of sexual dysfunction due to antipsychotic drug therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with sexual dysfunction due to antipsychotic drug therapy<BR/>
<B>Settings:</B> Outpatients<BR/>
<B>Intervention:</B> SWITCH to quetiapine versus MAINTENANCE risperidone<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SWITCH to quetiapine versus MAINTENANCE risperidone</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Sexual function: Subjective assessment (ASEX scale)</B>
<BR/>Follow-up: 6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean sexual function in the intervention groups was<BR/>
<B>2.02 lower</B>
<BR/>(5.79 lower to 1.75 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>36<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Sexual function: Subjective assessment (prolactin levels, ng/ml)</B>
<BR/>Follow-up: 6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean prolactin levels (ng/ml) in the intervention groups was<BR/>
<B>13.6 lower</B>
<BR/>(25.76 to 1.44 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>17<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Leaving the study early</B>
<BR/>Follow-up: 6 weeks</P>
</TD>
<TD>
<P>
<B>91 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>200 per 1000</B>
<BR/>(41 to 976)</P>
</TD>
<TD>
<P>
<B>RR 2.2 </B>
<BR/>(0.45 to 10.74)</P>
</TD>
<TD>
<P>42<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P>No attritions were reported for this study. The results are based on the number of participants with observations for the main outcome at the end of the trial.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects: Death</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: Psychopathology (PANSS)</B>
<BR/>Follow-up: 6 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean psychopathology in the intervention groups was<BR/>
<B>0.6 lower</B>
<BR/>(4.35 lower to 3.15 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>42<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects: Extrapyramidal symptoms</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> One trial provided data for this comparison. It was a short, small trial, and had an unclear risk of bias for random sequence generation and allocation concealment. It was also unclear is the outcome assessors were blinded. <BR/>
<SUP>2</SUP> The 95% confidence intervals around the pooled effect estimate include both significant benefit and harm of intervention. <BR/>
<SUP>3</SUP> This outcome was only reported in a sub-sample of participants. No explanation was provided why this was done.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2012-10-09 13:50:19 +0100" MODIFIED_BY="Grade Profiler" NO="4" READONLY="YES">
<TITLE MODIFIED="2012-07-10 14:15:43 +0100" MODIFIED_BY="Grade Profiler">SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE versus MAINTENANCE RISPERIDONE/FGA for management of sexual dysfunction due to antipsychotic drug therapy</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>SWITCH to olanzapine versus MAINTENANCE risperidone/FGA for management of sexual dysfunction due to antipsychotic drug therapy</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with sexual dysfunction due to antipsychotic drug therapy<BR/>
<B>Settings:</B> Outpatients<BR/>
<B>Intervention:</B> SWITCH to olanzapine versus MAINTENANCE risperidone/FGA<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>SWITCH to olanzapine versus MAINTENANCE risperidone/FGA</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Sexual function: Subjective assessment (GISF)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean sexual function in the intervention groups was<BR/>
<B>0.8 lower</B>
<BR/>(1.55 to 0.05 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>54<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Sexual function: Objective assessment (prolactin levels, ng/ml)</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean prolactin levels (ng/ml) in the intervention groups was<BR/>
<B>30.84 lower</B>
<BR/>(47.46 to 14.22 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>54<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Leaving the study early</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD>
<P>
<B>148 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>333 per 1000</B>
<BR/>(117 to 953)</P>
</TD>
<TD>
<P>
<B>RR 2.25 </B>
<BR/>(0.79 to 6.43)</P>
</TD>
<TD>
<P>54<BR/>(1 study)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Adverse effects: Death</B>
</P>
<P>Not reported</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No data were provided for this outcome.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: Psychopathology - various scales</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>41<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Psychopathology was measured on 4 scales (BPRS, PANSS, CGI-S MMSE), none of which showed a significant difference between treatment groups.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse effects: Extrapyramidal symptoms - various scales</B>
<BR/>Follow-up: 4 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>41<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Extrapyramidal symptoms were measured on 3 scales (Barnes Akathisia, Simpson-Agnus, AIMS), none showed a significant difference between treatment groups.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Only one trial provided data for this comparison. This trial had an unclear risk of bias for random sequence generation and allocation concealment. It has a high risk of bias for blinding as it was an open label trial.<BR/>
<SUP>2</SUP> The 95% confidence intervals around the pooled effect estimate include both significant benefit and harm of intervention. </P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Suggestions for trial of management of antipsychotic-induced sexual dysfunction</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Methods</P>
</TH>
<TH>
<P>Participants</P>
</TH>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Allocation: centralised sequence generation with table of random numbers or computer-generated code, stratified by severity of illness, sequence concealed till interventions assigned.<BR/>
<BR/>Blinding: those recruiting and assigning participants, those administering intervention, those assessing outcomes, all blind to allocated group, for interventions requiring medication, masking by means of identical looking tablets in same schedules.<BR/>
<BR/>Duration: 12 weeks, 26 weeks and 52 weeks.</P>
</TD>
<TD VALIGN="TOP">
<P>Diagnosis: schizophrenia (DSM IV), subtypes and schizoaffective disorder included and numbers in each category clearly reported.<BR/>
<BR/>N = 600.*<BR/>
<BR/>Age: adults.<BR/>
<BR/>Sex: men and women.<BR/>
<BR/>Setting: anywhere.<BR/>
<BR/>History: baseline score on scale such as BPRS or PANSS, stratified by cut off points into moderate and severe illness, taking routine antipsychotic drugs.</P>
</TD>
<TD>
<P>1. Dose reduction, i.e. the reduction of the dose of the agent causing the sexual dysfunction. N = 150.<BR/>
<BR/>2. Drug holidays, i.e. discontinuation of the drug 2-3 days before the anticipated sexual activity. N = 150.<BR/>
<BR/>3. Symptomatic therapy, e.g. the use of PDE-5 inhibitors. N = 150.<BR/>
<BR/>4. Switching to another antipsychotic drug which is meant to be less likely to cause sexual dysfunction. N = 150.<BR/>
<BR/>5. Placebo or no intervention (in the untreated control groups). N = 150.<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Improvement of sexual dysfunction**.<BR/>
<BR/>Adverse effects: including death.<BR/>
<BR/>Behaviour: leaving the study early.<BR/>
<BR/>Quality of life: including partner satisfaction.<BR/>
<BR/>Economic outcomes.<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>* size of study to detect a 10% difference in improvement with 80% certainty.<BR/>
<BR/>** Primary outcome.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BPRS: Brief Psychiatric Rating Scale<BR/>DSM: Diagnostic and Statistical Manual<BR/>PANSS: Positive and Negative Syndrome Scale<BR/>PDE-5: phosphodiesterase type 5 inhibitor<BR/>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-09 13:13:46 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-10-09 13:13:46 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>ADJUNCTIVE TREATMENT - SPECIFIC: SILDENAFIL versus PLACEBO</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="4.566486890021326" CI_START="1.8335131099786743" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="3.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.6595822151647951" LOG_CI_START="0.2632840195985255" LOG_DATA="NO" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2012-10-09 13:13:46 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="4.436970092589272E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="4.589787722317843">
<NAME>Sexual function (objective assessment): Number of erections sufficient for penetration (over 2 weeks)</NAME>
<GROUP_LABEL_1>Sildenafil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sildenafil</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean difference</EFFECT_MEASURE>
<IV_DATA CI_END="4.566486890021326" CI_START="1.8335131099786743" EFFECT_SIZE="3.2" ESTIMABLE="YES" ESTIMATE="3.2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-13 08:53:50 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SE="0.6972" STUDY_ID="STD-Gopalakrishnan-2006" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.8352159600317401" CI_START="0.5247840399682598" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="1.18" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.26368717743359626" LOG_CI_START="-0.2800193814432094" LOG_DATA="NO" LOG_EFFECT_SIZE="0.07188200730612536" MODIFIED="2012-09-24 12:20:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="4.159309985452827E-4" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="3.5297636853125933">
<NAME>Sexual function (objective assessment): Mean duration of erections (minutes)</NAME>
<GROUP_LABEL_1>Sildenafil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sildenafil</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.8352159600317401" CI_START="0.5247840399682598" EFFECT_SIZE="1.18" ESTIMABLE="YES" ESTIMATE="1.18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-13 08:53:53 +0100" MODIFIED_BY="[Empty name]" ORDER="149" SE="0.3343" STUDY_ID="STD-Gopalakrishnan-2006" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="4.071445371486516" CI_START="1.6085546285134837" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="2.84" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.609748612032915" LOG_CI_START="0.20643581466857183" LOG_DATA="NO" LOG_EFFECT_SIZE="0.45331834004703764" MODIFIED="2012-10-09 13:13:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="6.180059081376895E-6" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="4.520133694095177">
<NAME>Sexual function (objective assessment): Frequency of satisfactory intercourse (over 2 weeks)</NAME>
<GROUP_LABEL_1>Sildenafil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sildenafil</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean difference</EFFECT_MEASURE>
<IV_DATA CI_END="4.071445371486516" CI_START="1.6085546285134837" EFFECT_SIZE="2.84" ESTIMABLE="YES" ESTIMATE="2.84" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-13 08:53:55 +0100" MODIFIED_BY="[Empty name]" ORDER="150" SE="0.6283" STUDY_ID="STD-Gopalakrishnan-2006" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="21.126437700923617" CI_START="6.540900010099769" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="11.755250595854749" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.3248262733297471" LOG_CI_START="0.8156375101786201" LOG_DATA="YES" LOG_EFFECT_SIZE="1.0702318917541835" MODIFIED="2012-09-24 12:20:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.735826915587206E-16" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="8.239050484787697">
<NAME>Sexual function (subjective assessment): Improved erections ('yes') (GEQ)</NAME>
<GROUP_LABEL_1>Sildenafil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sildenafil</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds ratio</EFFECT_MEASURE>
<IV_DATA CI_END="21.126437700923617" CI_START="6.540900010099769" EFFECT_SIZE="11.755250595854749" ESTIMABLE="YES" ESTIMATE="2.4643" LOG_CI_END="1.3248262733297471" LOG_CI_START="0.8156375101786201" LOG_EFFECT_SIZE="1.0702318917541835" MODIFIED="2012-09-20 14:09:32 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SE="0.2991" STUDY_ID="STD-Gopalakrishnan-2006" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="4.223272848061776" CI_START="1.482885150504925" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="2.502524444020767" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.6256491402882194" LOG_CI_START="0.17110751621148637" LOG_DATA="YES" LOG_EFFECT_SIZE="0.39837832824985286" MODIFIED="2012-09-24 12:20:37 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="5.912857144872528E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0" Z="3.435580524344569">
<NAME>Sexual function (subjective assessment): Would take drug in future ('yes') (GEQ)</NAME>
<GROUP_LABEL_1>Sildenafil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sildenafil</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds ratio</EFFECT_MEASURE>
<IV_DATA CI_END="4.223272848061776" CI_START="1.482885150504925" EFFECT_SIZE="2.502524444020767" ESTIMABLE="YES" ESTIMATE="0.9173" LOG_CI_END="0.6256491402882194" LOG_CI_START="0.17110751621148637" LOG_EFFECT_SIZE="0.39837832824985286" MODIFIED="2012-09-20 14:10:33 +0100" MODIFIED_BY="[Empty name]" ORDER="152" SE="0.267" STUDY_ID="STD-Gopalakrishnan-2006" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.618637080220918" CI_START="0.014584119172649873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2012-09-24 12:20:37 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.49138352315933886" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.6881099923337485">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Sildenafil</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sildenafil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.618637080220918" CI_START="0.014584119172649873" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="147" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Gopalakrishnan-2006" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-09-24 12:21:48 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>ADJUNCTIVE TREATMENT - NON-SPECIFIC: SELEGILINE versus PLACEBO</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="3.1475348120174984" CI_START="-3.9475348120174982" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.49797054214240893" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-09-24 12:21:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.8250967349962601" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.22099447513812157">
<NAME>Sexual function (objective assessment): Average change in score (ASF, high=good)</NAME>
<GROUP_LABEL_1>Selegiline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selegiline</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean difference</EFFECT_MEASURE>
<IV_DATA CI_END="3.1475348120174984" CI_START="-3.9475348120174982" EFFECT_SIZE="-0.4" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-13 08:55:00 +0100" MODIFIED_BY="[Empty name]" ORDER="154" SE="1.81" STUDY_ID="STD-Kodesh-2003" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-09-24 12:21:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Selegiline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours selegiline</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="153" O_E="0.0" SE="0.0" STUDY_ID="STD-Kodesh-2003" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="2.0846331556575945" CI_START="-3.8846331556575944" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.31902964084892493" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2012-09-24 12:21:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5545093360623912" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.591016548463357">
<NAME>Adverse effects: Extrapyramidal symptoms - average change in score (SAS, high=poor)</NAME>
<GROUP_LABEL_1>Selegiline</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selegiline</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean difference</EFFECT_MEASURE>
<IV_DATA CI_END="2.0846331556575945" CI_START="-3.8846331556575944" EFFECT_SIZE="-0.9" ESTIMABLE="YES" ESTIMATE="-0.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-13 08:55:31 +0100" MODIFIED_BY="[Empty name]" ORDER="155" SE="1.5228" STUDY_ID="STD-Kodesh-2003" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.6060076764759528" CI_START="-0.6060076764759528" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.205747616810146" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2012-09-20 14:17:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.37558869869076406" Q="0.0" RANDOM="YES" SCALE="4.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0" Z="0.886053517632465">
<NAME>Adverse effects: Psychopathology - average change in scores (PANSS, high=poor)</NAME>
<GROUP_LABEL_1>Favours placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours selegiline</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.6060076764759528" CI_START="-0.6060076764759528" EFFECT_SIZE="0.5" ESTIMABLE="YES" ESTIMATE="0.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-20 14:17:21 +0100" MODIFIED_BY="[Empty name]" ORDER="156" SE="0.5643" STUDY_ID="STD-Kodesh-2003" TOTAL_1="5" TOTAL_2="5" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-09-24 12:22:20 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE versus MAINTENANCE RISPERIDONE</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.7469703444619893" CI_START="-5.786970344461988" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.0199999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2012-09-24 12:22:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.29325355553490895" Q="0.0" RANDOM="YES" SCALE="8.709321604678811" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="20" UNITS="" WEIGHT="100.0" Z="1.0510109947086308">
<NAME>Sexual function (subjective assessment): Average endpoint score (ASEX, high=bad)</NAME>
<GROUP_LABEL_1>Switch to quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7469703444619893" CI_START="-5.786970344461988" EFFECT_SIZE="-2.0199999999999996" ESTIMABLE="YES" MEAN_1="18.51" MEAN_2="20.53" MODIFIED="2012-06-07 16:53:55 +0100" MODIFIED_BY="[Empty name]" ORDER="11" SD_1="5.69" SD_2="5.78" SE="1.9219589615806056" STUDY_ID="STD-Byerly-2008" TOTAL_1="16" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.4417269438505986" CI_START="-25.758273056149406" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" MODIFIED="2012-09-24 12:22:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.02835234355777579" Q="0.0" RANDOM="YES" SCALE="51.90614392549857" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="2.1923763405085674">
<NAME>Sexual function (surrogate assessment): Prolactin levels, average endpoint (ng/ml)</NAME>
<GROUP_LABEL_1>Switch to quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.4417269438505986" CI_START="-25.758273056149406" EFFECT_SIZE="-13.600000000000001" ESTIMABLE="YES" MEAN_1="7.7" MEAN_2="21.3" MODIFIED="2012-06-18 11:10:25 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SD_1="4.8" SD_2="17.9" SE="6.203314526211863" STUDY_ID="STD-Byerly-2008" TOTAL_1="8" TOTAL_2="9" WEIGHT="100.0">
<FOOTNOTE>Prolactin reported in a sub-sample of participants</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.741838951265006" CI_START="0.45057461966789414" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.0310786368589526" LOG_CI_START="-0.34623327521454006" LOG_EFFECT_SIZE="0.3424226808222063" METHOD="MH" MODIFIED="2012-09-24 12:22:20 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.32977888316355997" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="99.99999999999999" Z="0.9745593805121568">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Switch to quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.741838951265006" CI_START="0.45057461966789414" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0310786368589526" LOG_CI_START="-0.34623327521454006" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2012-06-11 14:55:50 +0100" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.8090398349558905" STUDY_ID="STD-Byerly-2008" TOTAL_1="20" TOTAL_2="22" VAR="0.6545454545454545" WEIGHT="99.99999999999999">
<FOOTNOTE>No drop-outs reported, based on number of participants for the main outcome</FOOTNOTE>
</DICH_DATA>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.154378787990665" CI_START="-4.354378787990654" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.04" MODIFIED="2012-09-13 08:39:22 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.7541070768910278" Q="0.0" RANDOM="NO" SCALE="9.373062586236202" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.3132284878887791">
<NAME>Adverse effects: Psychopathology - average endpoint score (PANSS, high=poor)</NAME>
<GROUP_LABEL_1>Switch to quetiapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.154378787990665" CI_START="-4.354378787990654" EFFECT_SIZE="-0.5999999999999943" ESTIMABLE="YES" MEAN_1="71.5" MEAN_2="72.1" MODIFIED="2012-06-10 09:46:10 +0100" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="6.2" SD_2="6.2" SE="1.9155345800253065" STUDY_ID="STD-Byerly-2008" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-09-24 12:22:33 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE versus MAINTENANCE RISPERIDONE/FGA</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.045609510615885474" CI_START="-1.5543904893841147" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" MODIFIED="2012-09-24 12:22:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.03766692222972748" Q="0.0" RANDOM="YES" SCALE="3.202945862459739" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="2.078460969082653">
<NAME>Sexual function (subjective assessment): Average change in score (GISF, high=poor)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.045609510615885474" CI_START="-1.5543904893841147" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-0.6" MEAN_2="0.2" MODIFIED="2012-06-18 08:13:24 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="1.2" SD_2="1.6" SE="0.3849001794597505" STUDY_ID="STD-Kinon-2006" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0">
<FOOTNOTE>Product of LOCF assumptions</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-14.216057700887525" CI_START="-47.458142299112474" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-30.8371" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2012-09-24 12:22:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="2.7654932014647455E-4" Q="0.0" RANDOM="YES" SCALE="143.63744436634707" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" UNITS="" WEIGHT="100.0" Z="3.6363306404007796">
<NAME>Sexual function (surrogate assessment): Prolactin levels, average change (ng/ml)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="-14.216057700887525" CI_START="-47.458142299112474" EFFECT_SIZE="-30.8371" ESTIMABLE="YES" MEAN_1="-26.2815" MEAN_2="4.5556" MODIFIED="2012-06-18 10:49:49 +0100" MODIFIED_BY="[Empty name]" ORDER="217" SD_1="36.3296" SD_2="24.9373" SE="8.480279449121072" STUDY_ID="STD-Kinon-2006" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0">
<FOOTNOTE>Product of LOCF assumptions</FOOTNOTE>
</CONT_DATA>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.430146596537236" CI_START="0.7873070891923768" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.8082208742214916" LOG_CI_START="-0.10385583799876658" LOG_EFFECT_SIZE="0.3521825181113625" METHOD="MH" MODIFIED="2012-09-24 12:22:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.13012431852107378" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="27" WEIGHT="100.0" Z="1.5136118316245382">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.430146596537236" CI_START="0.7873070891923768" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8082208742214916" LOG_CI_START="-0.10385583799876658" LOG_EFFECT_SIZE="0.3521825181113625" MODIFIED="2012-06-18 07:52:58 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.5357583756107197" STUDY_ID="STD-Kinon-2006" TOTAL_1="27" TOTAL_2="27" VAR="0.28703703703703703" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="7.333966896193994" CI_START="-6.9339668961939935" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2012-09-13 08:48:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9561803843081647" Q="0.0" RANDOM="YES" SCALE="64.10935308455386" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.05494738097497218">
<NAME>Adverse effects: Psychopathology - average change in score (PANSS, high=poor)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.333966896193994" CI_START="-6.9339668961939935" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-4.2" MODIFIED="2012-06-20 08:55:24 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="10.5" SD_2="12.8" SE="3.639845911693181" STUDY_ID="STD-Kinon-2006" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.5045428805491514E-34" CI_END="3.9659909975159833" CI_START="-4.565990997515983" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.29999999999999977" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-004.05" MODIFIED="2012-09-13 08:48:27 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="1.0" P_Z="0.8903733556665809" Q="0.0" RANDOM="YES" SCALE="67.42741860899464" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.13783179470008078">
<NAME>Adverse effects: Psychopathology - average change in score (BPRS, high=poor)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.9659909975159833" CI_START="-4.565990997515983" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="-2.5" MEAN_2="-2.2" MODIFIED="2012-06-20 08:55:34 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="5.6" SD_2="8.3" SE="2.1765660140520824" STUDY_ID="STD-Kinon-2006" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.3934348687497684" CI_START="-0.5934348687497684" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.06" MODIFIED="2012-09-13 08:48:34 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.6912139032764912" Q="0.0" RANDOM="YES" SCALE="5.255407750888907" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.3972082454379597">
<NAME>Adverse effects: Psychopathology - average change in score (CGI-Severity, high=poor)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3934348687497684" CI_START="-0.5934348687497684" EFFECT_SIZE="-0.1" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-0.1" MODIFIED="2012-06-20 08:55:44 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="0.8" SD_2="0.8" SE="0.2517571101519822" STUDY_ID="STD-Kinon-2006" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.350811955762056" CI_START="-1.350811955762056" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.07" MODIFIED="2012-09-13 08:48:39 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="5.563706974442443" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Adverse effects: Psychopathology - average change in score (MMSE, high=good)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3508119557620557" CI_START="-1.3508119557620557" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.6" MODIFIED="2012-06-20 08:55:50 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="2.1" SD_2="2.3" SE="0.689202437604511" STUDY_ID="STD-Kinon-2006" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.4281319100112573" CI_START="-0.6281319100112572" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.08" MODIFIED="2012-09-13 08:48:44 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.7105536784556779" Q="0.0" RANDOM="YES" SCALE="6.592290148304762" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.37111258520589613">
<NAME>Adverse effects: Extrapyramidal symptoms - average change in score (BAS, high=poor)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4281319100112573" CI_START="-0.6281319100112572" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="-0.2" MODIFIED="2012-06-20 08:55:56 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="0.6" SD_2="1.1" SE="0.2694600075190638" STUDY_ID="STD-Kinon-2006" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.44747631532824916" CI_START="-2.247476315328249" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.09" MODIFIED="2012-09-13 08:48:49 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.19050391235693395" Q="0.0" RANDOM="YES" SCALE="15.267287626711902" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="1.3090898637846122">
<NAME>Adverse effects: Extrapyramidal symptoms - average change in score (SAS, high=poor)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.44747631532824916" CI_START="-2.247476315328249" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="0.5" MODIFIED="2012-06-20 08:56:02 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="2.0" SD_2="2.4" SE="0.6875005489677211" STUDY_ID="STD-Kinon-2006" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.594078314452325" CI_START="-1.194078314452325" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.10" MODIFIED="2012-09-13 08:48:54 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.5107640743207507" Q="0.0" RANDOM="YES" SCALE="8.394247935641806" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="18" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.6576484250400302">
<NAME>Adverse effects: Extrapyramidal symptoms - average change in score (AIMS, high=poor)</NAME>
<GROUP_LABEL_1>Switch to olanzapine</GROUP_LABEL_1>
<GROUP_LABEL_2>Risperidone/FGA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours switch</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours risperidone/FGA</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.594078314452325" CI_START="-1.194078314452325" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="0.2" MODIFIED="2012-06-20 08:57:32 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SD_1="1.1" SD_2="1.8" SE="0.4561707875780885" STUDY_ID="STD-Kinon-2006" TOTAL_1="18" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-05-23 11:59:55 +0100" MODIFIED_BY="[Empty name]">Previous search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Electronic Search : 2006</HEADING>
<P>We searched the Cochrane Schizophrenia Group's Register (June 2006), <I>The Cochrane Library</I> (Issue 2, 2005), MEDLINE (1966-8/2005), PsycLIT (1974-8/2005), EMBASE (1980-8/2005) and references of all identified studies for further trials. We contacted relevant pharmaceutical companies and authors of trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Searches: 2005</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 We searched The Cochrane Schizophrenia Group's Register (September 2005) with the phrase:</HEADING>
<P>(( "sex$" adj ( "dysfunction$" or "problem$" or "symptom$" )) or "anorgasm$" or "orgasm$" or "loss of libido" or "libido" or "lubrication" or "sexual arousal" or "sexual satisfaction" or "penile erection" or "impotence") and ( "treat$" or "therap$" ) and ( "neuroleptic$" or " antipsychotic$" or "major tranquilizer$" or "amisulpride" or "alimemazine" or "benperidol" or "bromperidol" or "chlorprothixene" or "clopenthixol" or "clozapine" or "dixyrazine" or "flupenthixol" or "fluphenazine" or "fluspirilene" or "haloperidol" or "levomepromazine" or "melperone" or "olanzapine" or "perazine" or "perphenazine" or "pimozide" or "pipamperone" or "promazine" or "promethazine" or "prothipendyl" or "quetiapine" or "reserpine" or "risperidone" or "sulpiride" or "thioridazine" or "trifluperazine" or "trifluperidol" or "triflupromazine" or "ziprasidone" or "zotepine" or "zuclopenthixol" )</P>
<P>Additionally, we searched Tthe Cochrane Schizophrenia Groups Trials Register (June 2006) using the phrase:</P>
<P>[((* sex*) in title of REFERENCE or (* sex* within same field as (dysfunction* or problem* or symptom*) in abstract or index terms of REFERENCE)or (orgasm* or libido*or lubrication*or sexual arousl*or sexual satisf*or penile erect*or impot*) in title or abstract or index terms of REFERENCE) OR ((sexual dysfunction or impotence) in health care conditions of STUDY or (sexual dysfunction or sexual function or sexual arousal or libido or erectile dysfunction) in outcomes of STUDY )]</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 We searched MEDLINE (Ovid 1966 - 8/2005) with the phrase:</HEADING>
<P>(( "sex$" adj ( "dysfunction$" or "problem$" or "symptom$" )) or "anorgasm$" or "orgasm$" or "loss of libido" or "libido" or "lubrication" or "sexual arousal" or "sexual satisfaction" or "penile erection" or "impotence") and ( "treat$" or "therap$" ) and ( "neuroleptic$" or " antipsychotic$" or "major tranquilizer$" or "amisulpride" or "alimemazine" or "benperidol" or "bromperidol" or "chlorprothixene" or "clopenthixol" or "clozapine" or "dixyrazine" or "flupenthixol" or "fluphenazine" or "fluspirilene" or "haloperidol" or "levomepromazine" or "melperone" or "olanzapine" or "perazine" or "perphenazine" or "pimozide" or "pipamperone" or "promazine" or "promethazine" or "prothipendyl" or "quetiapine" or "reserpine" or "risperidone" or "sulpiride" or "thioridazine" or "trifluperazine" or "trifluperidol" or "triflupromazine" or "ziprasidone" or "zotepine" or "zuclopenthixol" )</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 We searched PsycLIT (Ovid 1974 -8/ 2005) with the phrase:</HEADING>
<P>(( "sex$" adj ( "dysfunction$" or "problem$" or "symptom$" )) or "anorgasm$" or "orgasm$" or "loss of libido" or "libido" or "lubrication" or "sexual arousal" or "sexual satisfaction" or "penile erection" or "impotence") and ( "treat$" or "therap$" ) and ( "neuroleptic$" or " antipsychotic$" or "major tranquilizer$" or "amisulpride" or "alimemazine" or "benperidol" or "bromperidol" or "chlorprothixene" or "clopenthixol" or "clozapine" or "dixyrazine" or "flupenthixol" or "fluphenazine" or "fluspirilene" or "haloperidol" or "levomepromazine" or "melperone" or "olanzapine" or "perazine" or "perphenazine" or "pimozide" or "pipamperone" or "promazine" or "promethazine" or "prothipendyl" or "quetiapine" or "reserpine" or "risperidone" or "sulpiride" or "thioridazine" or "trifluperazine" or "trifluperidol" or "triflupromazine" or "ziprasidone" or "zotepine" or "zuclopenthixol" )</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 We searched EMBASE (1980- 8/2005) with the phrase:</HEADING>
<P>(( "sex$" adj ( "dysfunction$" or "problem$" or "symptom$" )) or "anorgasm$" or "orgasm$" or "loss of libido" or "libido" or "lubrication" or "sexual arousal" or "sexual satisfaction" or "penile erection" or "impotence") and ( "treat$" or "therap$" ) and ( "neuroleptic$" or " antipsychotic$" or "major tranquilizer$" or "amisulpride" or "alimemazine" or "benperidol" or "bromperidol" or "chlorprothixene" or "clopenthixol" or "clozapine" or "dixyrazine" or "flupenthixol" or "fluphenazine" or "fluspirilene" or "haloperidol" or "levomepromazine" or "melperone" or "olanzapine" or "perazine" or "perphenazine" or "pimozide" or "pipamperone" or "promazine" or "promethazine" or "prothipendyl" or "quetiapine" or "reserpine" or "risperidone" or "sulpiride" or "thioridazine" or "trifluperazine" or "trifluperidol" or "triflupromazine" or "ziprasidone" or "zotepine" or "zuclopenthixol" )</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 We searched CCTR/CENTRAL with:</HEADING>
<P>( "sex$" adj ( "dysfunction$" or "problem$" or "symptom$" )) and ( "treat$" or "therap$" ) and ( "neuroleptic$" or " antipsychotic$" or "major tranquilizer$" )</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Personal contact</HEADING>
<P>We contacted the first author of each included study for additional references and for any unpublished trials and data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Pharmaceutical companies</HEADING>
<P>We contacted companies involved in the production of the principal antipsychotic, who offer a drug information service and those that are involved in the production of the possible agents for symptomatic therapy and requested for additional studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.8. Citation searching</HEADING>
<P>We inspected the reference lists of all identified studies for additional studies.</P>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-05-23 12:02:40 +0100" MODIFIED_BY="[Empty name]">Previous methods sections</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-09 13:14:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Criteria for considering studies for this review  </HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of studies  </HEADING>
<P>We included all relevant randomised controlled trials. Where a trial was described as 'double-blind', but it was only implied that the study was randomised, we included these trials in a sensitivity analysis. We added these studies to the final analysis if there was no substantive difference within primary outcomes (see types of outcome measures). If there was a substantive difference, we used only clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by using alternate days of the week.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of participants  </HEADING>
<P>We included both men and women, of any age suffering, from sexual dysfunction (eg. penile erection, lubrication, orgasm, libido, sexual arousal or overall sexual satisfaction) as measured by criteria defined by the primary authors of the trials. The sexual dysfunction also had to be attributed to the antipsychotic drug therapy.</P>
<P>We considered the following antipsychotic drugs as potential causes of sexual dysfunction: alimemazine, amisulpride, benperidol, bromperidol, chlorprothixene, clopenthixol, clozapine, dixyrazine, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, melperone, olanzapine, perazine, perphenazine, pimozide, pipamperone, promazine, promethazine, prothipendyl, quetiapine, reserpine, risperidone, sulpiride, thioridazine, trifluperazine, trifluperidol, triflupromazine, ziprasidone, zotepine, zuclopenthixol.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of interventions  </HEADING>
<P>1. Dose reduction, i.e. the reduction of the dose of the agent causing the sexual dysfunction.<BR/>2. Drug holidays, i.e. discontinuation of the drug 2-3 days before the anticipated sexual activity.<BR/>3. Symptomatic therapy, e.g. the use of sildenafil or yohimbine.<BR/>4. Switching to another antipsychotic drug which is meant to be less likely to cause sexual dysfunction.<BR/>5. Placebo or no intervention (in the untreated control groups).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Types of outcome measures  </HEADING>
<P>We identified the following outcomes of interest:<BR/>1. Improvement of sexual dysfunction*<BR/>1.1 Objective assessment of improvement of sexual dysfunction by the trialists<BR/>1.1.1 Clinically significant improvement of sexual dysfunction as defined by the authors<BR/>1.1.2 Average score/change of sexual dysfunction<BR/>1.2 Subjective assessment of improvement of sexual dysfunction by the participants<BR/>1.2.1 Clinically significant improvement of sexual dysfunction as defined by the authors<BR/>1.2.2 Average score/change of sexual dysfunction</P>
<P>2. Adverse effects<BR/>2.1 Death<BR/>2.2 Other specific adverse effects</P>
<P>3. Leaving the study early</P>
<P>4. Quality of life<BR/>4.1 Improvement of quality of life - as defined by each of the studies<BR/>4.2 Average score/change of quality of life</P>
<P>6. Economic outcomes (costs of therapy)</P>
<P>* Primary outcome</P>
<P>We reported all outcomes for the short term (up to 12 weeks), medium term (13-26 weeks), and long term (more than 26 weeks).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data collection and analysis  </HEADING>
<P>1. Selection of trials<BR/>We (MB and MH), working independently, inspected citations identified in the search outlined above. We identified potentially relevant abstracts and ordered full papers and reassessed these for inclusion and methodological quality. We discussed any disagreement.</P>
<P>2. Assessment of quality<BR/>Again, working independently, we allocated trials to three quality categories, as described in The Cochrane Collaboration Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). When disputes arose as to which category a trial should be allocated, again, we attempted resolution by discussion. Where this was not possible, and further information was necessary, data were not entered into the analyses and we listed the study in those awaiting assessment. We only included trials in Category A or B in the review, because there is empirical evidence that bad quality of randomisation can produce biased results (<LINK REF="REF-Chalmers-1983" TYPE="REFERENCE">Chalmers 1983</LINK>; <LINK REF="REF-Schultz-1995" TYPE="REFERENCE">Schultz 1995</LINK>).</P>
<P>3. Data management<BR/>3.1 Data extraction<BR/>We (MB and MH) independently performed data extraction and where further clarification was needed we contacted the authors of trials to provide missing data. Data from foreign language studies were to have been extracted with the help of a translator.</P>
<P>3.2 Intention to treat analysis<BR/>We would have excluded studies where more than 50% of participants in any group were lost to follow up (this does not include the outcome of 'leaving the study early'). We felt that with such a great degree of attrition, great assumptions would have to be made, and these would threaten the validity of any findings. In studies with less than 50% dropout rate, we would have considered people leaving early to have had the negative outcome, except for the event of death and other rare adverse events.</P>
<P>4. Data analysis<BR/>4.1 Binary data<BR/>We calculated random effects relative risk (RR) and its 95% confidence interval (CI) on the basis of a random effects model for binary outcomes. The random effects model integrates heterogeneity between studies, even when this heterogeneity is not statistically significant. We calculated the number needed to treat statistic (NNT) in the case of statistically significant results.</P>
<P>4.2 Continuous data</P>
<P>4.2.1 Rating scales: a wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. Continuous data from rating scales were included only if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by an independent rater or relative (not the therapist), and the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, such data were commented on with 'prone to bias'.</P>
<P>4.2.2 Skewed data: continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to all endpoint data before inclusion: (a) standard deviations and means are reported in the paper or were obtainable from the authors; (b) when a scale start from a finite number (such as zero), the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution). Endpoint scores on scales often have a finite start and end point and this rule can be applied to them. However, if a scale starts from a positive value the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skewness is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
<P>4.2.3 Endpoint versus change data: endpoint scale-derived data are finite, ranging from one score to another. Change data are more problematic and for it the rule described above does not hold. Although most change scores are likely to be skewed, this cannot be proven so they were presented in MetaView. Where both endpoint and change were available for the same outcome, we presented the former in preference.</P>
<P>4.2.4 Summary statistic: for continuous outcomes, we calculated a weighted mean difference (WMD) between groups. Again, we used a random effects model.</P>
<P>4.3 Cluster trials<BR/>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated, this causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>; <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Secondly, RevMan does not currently support meta-analytic pooling of clustered dichotomous data, even when these are correctly analysed by the authors of primary studies, since the 'design effect' (a statistical correction for clustering) cannot be incorporated.</P>
<P>Where clustering was not accounted for in primary studies, we would have presented data in a table, with an asterisk (*) symbol to indicate the presence of a probable unit of analysis error. Subsequent versions of this review would seek to contact first authors of studies, to seek intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering was incorporated into the analysis of primary studies, then we would have presented these data in a table. No further secondary analysis (including meta-analytic pooling) would have been attempted until there is consensus on the best methods of doing so, and until RevMan, or any other software, allows this. A Cochrane Statistical Methods Workgroup is currently addressing this issue. In the interim, individual studies would have been very crudely classified as positive or negative, according to whether a statistically significant result (p&lt;0.05) was obtained for the outcome in question, using an analytic method which allowed for clustering.</P>
<P>4.4 Cross-over trials (amendment to original protocol)<BR/>Because, within cross-over studies, intervention and control group measures are correlated, paired analyses, accounting for this correlation, is needed (apart from drop-out rates, as participants can leave the study only once). For continuous outcomes, weighted mean differences can be calculated. For these studies we reported dichotomous outcomes as odds ratios. This is because odds ratios rather than risk ratios are proposed for cross-over trials (<LINK REF="REF-Curtin-2002b" TYPE="REFERENCE">Curtin 2002b</LINK>). All analyses were based on the recommendations by <LINK REF="REF-Curtin-2002a" TYPE="REFERENCE">Curtin 2002a</LINK> and <LINK REF="REF-Curtin-2002b" TYPE="REFERENCE">Curtin 2002b</LINK>. We used the generic inverse variance method to enable individually optimised strategy for each study. In the main we calculated standard error of estimates from exactly reported t or p statistics.</P>
<P>5. Test for heterogeneity<BR/>We used a Chi-square test, as well as visual inspection of graphs, to investigate the possibility of heterogeneity. We interpreted a significance level less than 0.10 as evidence of heterogeneity. If we found heterogeneity, studies outlying would have been closely inspected in order to find reasons for the heterogeneity. If clear reasons for the heterogeneity had been found, we would not have added responsible studies to the main body of homogeneous trials, but summated and presented these separately and investigated reasons for heterogeneity. Additionally, we used the I-squared statistic to quantify the extent of heterogeneity. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Had the I-squared estimate been greater than or equal to 50%, we would have interpreted this as indicating the presence of considerable levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
<P>6. Addressing publication bias<BR/>Had sufficient trials been identified, we would have entered data from all included studies into a funnel graph (trial effect against trial size) in an attempt to investigate the likelihood of overt publication bias.</P>
<P>7. Sensitivity analyses<BR/>We would have analysed the effect of including studies with high attrition rates in a sensitivity analysis. Two further sensitivity analyses were to have been performed; first to see the influence of including studies judged low in methodological quality (category B for allocation concealment and categories B or C for double blinding); and, second, to examine whether the decision to perform an intention-to-treat analysis affected the final results of the review compared to an analysis that did not count people who were lost to follow-up.</P>
<P>8. Subgroup analyses<BR/>Subgroup analyses should be performed and interpreted with caution because multiple analyses will lead to false positive conclusions (<LINK REF="REF-Oxman-1992" TYPE="REFERENCE">Oxman 1992</LINK>). For this reason we did not plan or carry out any subgroup analyses.</P>
<P>9. General<BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for the strategies against sexual dysfunction.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>